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ABSTRACT 
 
Cystinosis is a metabolic disorder characterised by the abnormal 
accumulation of the amino acid cystine in cells leading to a slow 
destruction of all major organs.   If patients diagnosed with cystinosis are 
untreated, death due to kidney failure ensues in the second decade of life.   
A number of studies have shown the ability of the drug cysteamine 
(Cystagon®) to lower cystine accumulation within cells resulting in reduced 
organ and tissue damage.  Cysteamine therapy however, is associated 
with a number of side effects involving the gastrointestinal tract and the 
central nervous system.  Most of these arise due to the large amount of 
cysteamine present in the stomach and gut following administration.  In 
addition, cysteamine possesses an unpleasant taste and smell, resulting in 
poor patient compliance.  In an attempt to overcome these problems, a 
number of pro-drug derivatives of cysteamine and cystamine, the disulfide 
analogue of cysteamine, have been synthesised and evaluated. 
Pro-drugs were synthesised using a route established in our laboratories.  
Briefly, cystamine dihydrochloride was basified and allowed to react with a 
number of cyclic anhydrides under basic conditions. The resulting di-acids 
were reacted with carbonyldiimidazole and monoBoc-cystamine to yield 
the desired pro-drugs.  Removal of the tBoc-protecting group was 
achieved in a facile manner by use of trifluoroacetic acid to yield product. 
The efficacy of the synthesised pro-drugs was determined by incubation of 
50µM compound in a suspension of cultured cystinotic fibroblasts, with 
50µM cysteamine as control.  Cell growth was measured at 72 h and the 
level of thiol determined.   
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All except one of the pro-drugs tested were significantly more effective than 
the control at lowering the cystine burden of the cells.  
Further work will concentrate on repeating these studies and evaluating a 
more robust Structure Activity Relationship for these compounds. 
 
The overall aim of all this work remains the production of an odourless, 
tasteless and orally active treatment for cystinosis and, if possible, improve 
on the current dosing regimen of every 6h.  By using pro-drugs, cysteamine 
will be chemically camouflaged and hence, the side effects associated with 
its administration will be minimised or even entirely abolished. 
 
Keywords:  Nephropathic Cystinosis, Cystagon®, cysteamine, cystamine, 
pro-drugs, multicomponent crystals, peptide synthesis. 
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INTRODUCTION 
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1.1. Nephropathic Cystinosis   
                                                                                                                
1.1.1. Background and Historical Aspects 
 
Cystinosis is a rare inherited autosomal recessive disorder, characterised by 
a high accumulation of the amino acid cystine in various organs and tissues, 
resulting in severe organ dysfunction.1,2    
Cystine is a non-essential amino acid for human development and was first 
discovered by Wollaston in 1810.3 The disulfide derivative cystine (a) is 
produced by the oxidation of two molecules of cysteine (b).  Sulfur bridges 
of this type occur naturally both within and between polypeptides, often 
found in extracellular proteins.3 
 
 
H3N
O
S
S
H NH3
H
O
O
O
(a)
O
O
H3N
SH
(b)
H
 
 
Human proteins are composed of natural amino acids known as L-series 
amino acids (Figure 1).  This is because the NH3
+ group positioned on the 
left-hand side of the Fisher projection makes their configuration comparable 
to that of L-(-)-glyceraldehyde, where the most oxidised carbon is drawn at 
the top.4 (Figure 2)  Furthermore, in the Cahn-Ingold-Prelog (CIP) 
convention, “ all the common L-series amino acids are (S) unless the side-
chain contains a sulfur atom.’’ 4 This is the case for the amino acid L-
cysteine where one sulfur atom in the side-chain takes priority over the two 
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oxygens in the COO- group. The CIP convention of L-cysteine is therefore 
(R).4 (Figure 3) 
 
  R
H3N
+ H
COO
-
                                   
CHO
CH2OH
HHO
                                                                                                       
Figure 1.: Fisher projection of L-series amino acids                Figure 2.: L-(-)-Glyceraldehyde               
 
 
 
 
                       Figure 3.: Cahn-Ingold-Prelog convention for L-Cysteine. 
 
 
Cystinosis was first reported in 1903 by the scientist Emil Abderhalden, following 
an autopsy performed on a child with severe growth failure.  Abderhalden’s 
findings revealed the presence of cystine crystals in the liver and spleen.5  In 
1924, the observations made by Aberhalden were further developed by Lignac 
who identified frequent cases of children with profound rickets.6  Clinical 
understanding of the disease only matured in the early 1930s when cystinosis 
was first classified as a cystine storage disease (CSD) by the paediatrician Guido 
Fanconi 7,8,9, where an increase in the lysosomal cystine level to almost 100 fold 
was discernible in isolated fibroblasts and lymphocytes from cystinosis patients 
compared to normal individuals.7,10 
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Cystine, unable to cross the cell membrane accumulates as crystals in 
various tissues excluding leucocytes.7,11 
Initially, it was anticipated that the severity of the phenotype would be 
relatively proportional to the content of intracellular cystine.7,12  However, an 
in vitro cystine loading replica of cystinosis failed to demonstrate this 
relationship between the build up of intracellular cystine level and renal 
tubular dysfunction.7,13  
 
Furthermore, irregularities in energy production in patients with cystinosis 
seemed to be linked to lysosomal cystine storage.7 This reduction in 
intracellular ATP levels14,15 which originates from a decrease in intracellular 
glutathione within the proximal tubule, triggers hypoxic stress followed by 
apoptosis, resulting in the progressive lesion of the glomerulotubular 
junction.16,17   The latter, described as the “swan-neck deformity” (Figure 4) 
is another common hallmark of cystinosis.18 
 
 
 
Figure 4.: Image illustrating a marked atrophy of proximal tubules (A and B) of 
microdissected nephrons removed from a cystinosis patient. 19,20 
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In normal physiological conditions, certain substances such as glucose and 
sodium are reabsorbed by the renal tubules and returned to the blood.  
However, Fanconi point out that in cystinosis the renal tubules fail to 
reabsorbe these substance causing them to pass into the urine.6  
Generally, this progressive renal tubular dysfunction will eventually lead to 
interstitial nephritis and ultimate necrosis21 resulting in only small quantities 
of dietary vitamin D from being reabsorbed.  This in turn will prevent 
reabsorption of calcium and potassium ions.22-28 
 
This tubulopathy was further confirmed by Debre et al. and De Toni who 
reported urinary secretion of organic acids and phosphates also known as 
rickets.6,29,30 Subsequently, Fanconi referred to cystinosis as  “ nephrotic-
glycosuric dwarfism with hypophosphatemic rickets.’’(1936) 6,31   
 
By 1952 Bickel et al. noted a relationship between Fanconi’s syndrome and 
progressive kidney damage in a large number of cystinotic children.6 
 
Ion exchange chromatography was first used in 1967 for amino acid 
analysis.  This technique allowed the detection of infinitesimal amounts of 
cystine present in tissue samples of young cystinosis patients.8,32 
Subsequent studies such as the one by Schneider et al. reported an 
abnormality in heterozygotes.  These findings were demonstrated by the 
measurements of the free cystine concentration in leucocytes of patients’ 
parents which was about 6 times normal.33 
Moreover, Teree et al. noted a renal tubulopathy following a microdissection 
from two male siblings. The results suggested that the progression of the 
abnormality was inevitable.34 
 
In 1970 a medical innovation dramatically altered the course of research on 
cystinosis when Mahoney et al. not only proved an excellent renal allograft 
survival in four cystinotic children but clear evidence that glomerular and 
tubular cellular changes of cystinosis did not progress or recur.6  As a result 
of this outcome, the natural history of cystinosis was transformed.  
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Up until the early 1970s when renal transplantation was first recognised for 
its health given, the prognosis of a child with cystinosis was poor with a 
lifespan of only 10 years.  As a result of the progress in medical and surgical 
interventions, infantile cystinosis was no longer considered as a fatal 
disease.35  
Cystinosis was also classified as the first lysosomal storage disease (LSD) 
owing to a defective lysosomal membrane transport.7 
Consequently, increased cystine concentration within cellular lysosomes will 
result in crystal formation causing organ and tissue damage including; the 
central nervous system (CNS), eyes, pancreas, thyroid, and principally 
tubular cell destruction, leading to Fanconi’s syndrome.36 
As previously stated, Fanconi’s syndrome will eventually lead to an 
increased damage to the renal tubules, preventing them from performing 
their normal reabsorptive function 37,38 of sodium, bicarbonate, potassium, 
phosphate, glucose, amino acids, uric acid, low-molecular-weight proteins 
and peptides.39  These losses will contribute to severe dehydration in 
infants.36 Nevertheless, LSD was the first group of progressive disorder to 
be identified as a treatable disease.21,40 One of the characteristics of LSDs is 
the absence of signs of abnormality at birth.  The first symptoms of 
glomerular dysfunction are displayed in children between the ages of 6-12 
months to 2 years 41 and if untreated, these children will develop an end-
stage renal failure before their 10th birthday.21 
Crystals of cystine (a) accrue predominantly within cellular lysosomes which 
are defined as small sacs each delimited by a single lipoprotein membrane. 
Their core functions are to digest, process and arrange cellular components. 
Lysosomes are found in virtually every living cell and contain several dozen 
different enzymes principally acid hydrolases catalysing reactions of the 
type: 
 
A-B  +  H2O A-H    +   B-OH 
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These enzymes produced from the Golgi apparatus are responsible for the 
breakdown of virtually all large cellular molecules including nucleic acids, 
proteins, polysaccharides, and lipids, to low-molecular-weight products. 42,43 
Lysosomes (Figure 5) are also described as intracellular hydrolytic 
organelles where materials to be digested are incorporated within the same 
membrane-bounded compartments as the lysosomal enzymes. As result of 
this compartmentation, a low-pH environment needed for efficient activity 
of the enzymes hydrolases can be established. 43,44  
 
 
 
 
                  Figure 5.:  Lysosome 45 
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1.1.2. Epidemiology of Cystinosis 
 
The worldwide incidence of cystinosis is approximately 1:100,000 to 
1:200,000 live births.8,46,47  These cases have been reported amongst all 
ethnic groups.7,48  A higher rate of 1 in 26,000 was found in the Western 
French Province of Brittany due to a founder effect.  The incidence in the 
rest of France is 1 case per 326,440 population.7,48,49 
In particular, nephropathic cystinosis accounts for more than 95% of the 
cases, with an incidence of 1 case per 100, 000 to 200,000 live births in 
North America.7,50,51,52    In the United States (U.S.) alone, around 15 new 
cases are diagnosed each year.2 In Europe, cystinosis has been estimated to 
affect between 1:115,000 and 1:179,000 live births, with an estimate of 
200 cystinotic patients in the United Kingdom (UK).7,50,51  
 
1.1.3. Aetiology of Cytinosis 
 
       Race 
The physical characteristics in patients of European descent include blonde 
hair, blue eyes, and short stature.  Cystinosis also occurred in other races 
around the globe including blacks and Hispanics.35 (Figure 6)  
 
 
Figure 6.: Patients with Nephropathic Cystinosis.
8 
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      Sex 
A ratio of 1:4 male to female has been reported amongst cystinotic 
children.35 
      Age 
Children affected by this disease appear normal at birth but 6 to 12 months 
later progressively develop signs and symptoms of dehydration, acidosis, 
polydipsia, polyuria, failure to thrive, photophobia and rickets.53,54    
Poor muscular development has also been noted.  Infants will display signs 
of renal tubular Fanconi syndrome in their first six months of life.23 
In the intermediate (adolescent) form, symptoms become obvious by age 
8-12 years.  Moreover, in this category, the disease progresses at a much 
slower pace.  
The benign (adult) form of cystinosis is referred to as the ocular form due to 
the presence of crystals in the cornea.  In this form kidneys are spared from 
the disease. 35,52 
 
1.1.4. Cystinosis sub-categories 
 
Cystinosis has been categorised into 2 general phenotypes, nephropathic 
and non-nephropathic cystinosis.35,52  
Based on both the severity of the symptoms and the age of onset, 
cystinosis has been further subdivided into three clinical forms.  
(i) The late-onset or intermediate form is the more indolent form of the 
disease and affects only a minority of patients (~5%).8,55,56  
This nephropathic juvenile form of the disease is characterised by 
photophobia and mild proximal tubulopathy which slowly progress to 
chronic renal failure 57 after the age of 15.35 The onset of the latter 
commonly occurs at the age of adolescence, regardless of displaying all the 
signs of the nephropathic form.7  Patients affected by this form of the 
disease display symptoms which are only limited to kidneys manifested by 
proteinuria and a milder form of the Fanconi syndrome.35 
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(ii) The non-nephropathic cystinosis or the benign (ocular) form which 
generally occurs in adulthood is characterised by isolated photophobia with 
the absence of renal anomalies.57 In this category, cystinosis is commonly 
detected in patients receiving treatment for photophobia.  Fortunately for 
this group of patients, photophobia is less debilitating than in the 
nephropathic form.35 The presence of corneal crystal deposits is confirmed 
by a routine slit-lamp examination.  Additionally, cystine crystals have also 
been located in the bone marrow and leucocytes but were absent in both 
the retina and the kidney.35,55,58,5 
 
(iii) Nephropathic or classic infantile cystinosis is the most severe variant, 
where terminal renal failure is inevitable.  In general, patients with infantile 
cystinosis are born from uncomplicated pregnancies with normal birth 
weight and length and do not display any clinical symptoms regardless of 
cystine being present in the uterus.7 
The most common characteristics of nephropathic cystinosis are; poor 
growth, renal glomerular failure, and tissue and organ impairment such as 
the pancreas, CNS and thyroid.36 Nephropathic cystinosis is also considered 
the major identifiable cause of renal Fanconi syndrome 8; a clinical feature 
resulting from the accumulated cystine in the kidneys.36    
 
1.1.5. Symptoms of Cystinosis   
 
The most common symptoms of cystinosis are summarised in Table 1. 
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            Table 1.: Common symptoms of cystinosis 
 
Organ/System                                   Symptoms 
    Kidney                                             Polyurea 
                                                        Polydipsia 
                                                       Renal failure 
   Hepatic                                         Hepatomegaly 
   Ocular                                            Photophobia                                
                                                     Retinal blindness   
                                                    Visual impairment      
  Endocrine                                       Hypothyroidism                                                                                             
                                                      Diabetes mellitus 
  Musculo-skeletal                           Muscle wasting 
                                                   Rickets 
                                        Swallowing  difficulties 
                                        Inter-costal muscle weakness 
  Reproductive                                Male hypogonadism 
                                                 Azoospermia 
  CNS                                   Epilepsy mental deterioration 
                                           Cerebella and pyramidal signs 
                                                Stroke-like episodes       
Other                                            Short stature 
 
                
In nephropathic cystinosis certain factors responsible for multi-organ 
symptoms to progress from mild to severe include; patient’s age at the time 
of diagnosis, age of patient when treatment is first initiated, and genetic 
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factors.  In the past, clinical symptoms of nephropathic cystinosis would 
always follow a predicted chronological pattern.   
At the age of 1 year infants display symptoms of poor growth, proximal 
tubular and Fanconi’s syndrome followed by end stage renal disease (ESRD) 
at 10 years.8,35,53,55  However, the rate at which ESRD develops varies from 
one patient to another.  Some patients will experience rapid deterioration of 
their renal function, whereas others reach a plateau.7,8 
Patients with nephropathic cystinosis experience other symptoms of 
constipation, poor/loss of appetite, craving of salty and hot and spicy foods, 
recurrent bouts of fever and manifestations of heat intolerance.   These 
patients also go through failure in thriving which is due to secondary 
symptoms, namely; vomiting, anorexia, and difficulties in feeding.  Infants 
between 6 to 12 months will experience growth deficit, and only 60% of the 
normal growth rate is seen after the age of 1 year.7,35,60 
 
1.1.6. Impact of the disease on the kidneys 
 
Increased sodium chloride concentration resulting from impaired proximal 
tubules has been identified as a possible contributing factor to glomerular 
failure.  The latter occurs when the activation of glomerular-tubular 
feedback mechanism is triggered causing the rate of glomerular filtration to 
decrease.7,61,62   This irreversible damage in the proximal tubules prevents 
water, electrolytes, bicarbonate, calcium, glucose, phosphate, carnitine, 
amino acids and tubular proteins and many other solutes from being 
reabsorbed in this nephron segment.5,7 This in turn has led to a number of 
pathological complications namely: 
 
Hyperaminoaciduria has been recognised as the hallmark of Fanconi’s 
syndrome.7,55,63,64,65  In general, over 98% of amino acids are reabsorbed by 
the proximal tubules.  However, in children with cystinosis 
hyperaminoaciduria occurs as a result of a considerable loss of amino acids 
(6-16 times) greater than in normal children, whose daily excretion is only 1 
to 6 mg per kilogram (kg) of body weight.66 
  
 
 
27 
 
Glycosuria is also indicative of renal damage as normal serum glucose 
concentration suggests an abnormally low renal glucose threshold.66  
Additionally, owing to similarities in the urine output, the diagnosis of 
cystinosis can be masked by diabetes insipidus.50 
 
Metabolic acidosis is caused by a fall in serum bicarbonate concentrations 
due to a reduced threshold for bicarbonate reabsorption.  The resulting 
bicarbonate excess in the distal tubule augments potassium excretion 
causing severe hypokalemia, leading to subsequent risks of developing 
cardiac dysfunction.7,63 Additonally, in children with cystinosis, this 
metabolic acidosis is partly accountable for their poor growth.7,63 
 
Hypovolemia occurs as a result of profound polyuria, polydipsia, 
dehydration and hypochloremic metabolic acidosis.  Patients affected by this 
condition will require urgent medical treatment.7 
 
Vitamin D-resistant hypophosphatemic rickets and Osteomalacia are 
conditions affecting children and adults respectively.  These arise from a 
lack of reabsorption of calcium and phosphate by the proximal tubule.7,66 
 
Nephrocalcinosis and renal stones are likely to develop as a result of 
hyperphosphaturia and hypercalciuria.55,67,68  
Alpha-1-microglobulin, retinol-binding protein and beta-2-microglobulin are 
all low-molecular weight (LMW) proteins and are mainly excreted by 
cystinotic patients.7,55,65,69,57  Others such as large molecular proteins known 
as glomerular proteins have been found in the urine of patients with severe 
end stage glomerular function.66 The presence of enzymes, hormones and 
immunoglobulins in the urine of patients suffering from Fanconi’s syndrome 
has also been reported 7 as well as a deficit in both plasma and muscle 
cartinine in children.7,71 
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 1.1.7. Impact of the disease on the eye 
 
Cystine crystals were first identified by Burki in 1941, following a slit-lamp 
examination of the eye of a cystinosis patient.72 The crystals were described 
as crystalline deposits, evenly distributed in both the posterior sections 
(optic nerve and retina) and the anterior ophthalmic fragments 
(conjunctiva, iris, cilliary body and cornea).73,74,75,76 The crystals become 
visible at the age of 1 year and will continue to deposit progressively with 
age, becoming more dense and prominent especially in the cornea part of 
the eye with a ground glass opaque appearance.  
(Figure 7).73,77,78  
 
 
 
 Figure 7.: Corneal cystine crystals from patients with Cystinosis during slit-
lamp examination 79 
 
This crystal growth results in major ocular complications mainly 
photophobia and, ultimately, blepharospasm causing great discomfort when 
in direct sunlight which in children can be very troublesome and 
debilitating.41 
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1.2. Genetics 
 
The inheritance of an autosomal recessive disorder such as cystinosis will 
occur in a child when both parents are carriers of the abnormal gene. Due 
to the recessive nature of the gene, parents do not exhibit the disease but 
have the potential to pass it onto their offspring as shown in Figure 8.80 
 
 
                         
                               Figure 8.:  Inheritance pattern of Cystinosis.81  
 
 
This metabolic disorder arises due to mutations occurring in the CTNS gene 
found on chromosome 17p13 (Figure 9) coding for the lysosomal transport 
protein cystinosin.82,83   
These mutations have been reported in all cystinotic patients with the most 
common mutation being a 57-Kb deletion present in approximately 50% of 
cystinotic patients of Western European ancestry.83,84   In the United States 
of America and the Northern European population, this deletion present in 
the homozygous state, has been reported in almost 40% of cystinosis 
patients.85  In 2004, the development of a fluorescent in situ hybridisation 
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test assisted in the detection of the 57-kb deletion with 100% specificity 
and 100% sensitivity.86   
Samples of chorionic villi or cultured amniocytes can be used to perform 
prenatal diagnostic tests.86  
 
Patients affected by the most severe form of the disease possess mutations 
on both alleles status of the CTNS gene and display multiple manifestations.  
The detection of these mutations in all forms of the disease confirmed their 
allelic status.87 The normal function of this gene is to provide directions for 
the manufacture of the transport protein cystinosin which is situated inside 
the lysosomal membrane.   
 
         Figure 9.: Cytogenetic Location of chromosome 17p13 (CTNS) 88 
 
 
 
Cystinosin (Figure 10) is a 367-amino acid protein with seven 
transmembrane domains and two lysosomal targeting motifs.89 Cystinosin is 
specifically responsible for the export of the amino acid cystine across the 
lysosomal membrane and into the cytoplasm.11,90  This transport process is 
defective in cystinosis sufferers resulting in an accumulation of the poorly 
soluble cystine in the lysosomes.  
  Cytogenetic Location   
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Figure 10.: Cystinosin in the lysosomal membrane 8 
 
 
1.3. Diagnosis 
 
The normal physiological values of cystine are ≤0.2nmol half-cystine/mg 
protein, whereas the abnormal values range between 3.0 to 23 nmol half-
cystine/mg protein.11  Therefore, the markedly elevated levels of the 
intracellular leucocyte cystine play an important role in the definitive 
diagnosis of cystinosis.  The detection of renal tubular Fanconi syndrome  
between the ages of 6 and 12 months, followed  by photophobia and 
hypothyroidism by the age of 10 and finally renal failure by the age of 12 
can also assist in the diagnosis of nephropathic cystinosis.91   
In addition, the detection of corneal crystals by slit-lamp examination of the 
cornea is another diagnostic test for cystinosis.92   Tissue accumulation of 
cystine remains the diagnostic trademark of cystinosis.   
 
        1.4. Treatment and prevention of early manifestations 
 
The goals of therapy in the management of nephropathic cystinosis seek to 
relieve the symptoms and to treat the underlying pathology.  If patients 
diagnosed with cystinosis are untreated, death ensues in the second decade 
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of their life.  The care of cystinosis patients involves the use of a number of 
therapeutic modalities: 
Primarily and most importantly, excessive loss of fluids and electrolytes 
resulting from defective renal absorption (renal Fanconi syndrome) are 
replenished through adequate amounts of water, and supplementation with 
salts and minerals in particular citrate in order to alkalinise the blood. 
7,51,93,94 
Acidosis is controlled by a daily use of anions mainly bicarbonates, acetate 
or citrate salts (2-10 mEq/kg/day).7,71 
Metabolic acidosis can only be managed by either bicarbonate or citrate; 
supplementation with potassium is also required.7,95  Phosphate 
replacement therapy is also required with a daily supplementation of 1-3 g 
of neutral phosphate complemented with vitamin D for better absorption.71  
Although thiazide diuretics have been successfully used in the past for the 
treatment of Fanconi’s syndrome in order to increase proximal tubular 
reabsorption of bicarbonates, however, patients with cystinosis have not 
benefited from this therapy.7 
 
Cystinosis patients often suffer from feeding difficulties and caloric intake 
can be problematic, nevertheless, the provision of essential nutrients for 
growth development has been made possible via a gastric tube.  However, 
early withdrawal from this nutritional support is always recommended and 
has been proven possible with successful cystine depletion therapy.7,96 
Growth hormone therapy is also used to correct poor growth 51,93,94,97 and 
has benefited children with cystinosis as it helped enhance their 
development.98  These hormones are not usually required for those who are 
well-treated as they have shown good growth.   It has also being reported 
that the use of these hormones assisted in the increase of phosphate 
reabsorption.7,63  
Severe glomerular proteinuria can be alleviated with the use of angiotensin 
converting enzyme (ACE) inhibitors, but caution should be shown when 
using this class of drugs due to blocking volume compensation 
mechanisms.7,96  Patients with ESRD who are awaiting renal transplantation 
will temporarily undergo both hemodialysis and peritoneal dialysis.7,96 
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A typical treatment regimen in cystinosis will involve an exhaustive list of 
medication including, levothyroxine used for the treatment of 
hypothyroidism, glibenclamide and insulin to control diabetes, sodium 
valproate for epilepsy, ciclosporin, and prednisolone.51   
These conditions occur secondary to cystinosis due to cystine accumulation 
in the thyroid, pancreas, and central nervous system. 
Most children will also be supplemented with solutions of calcium (Ca) and 
phosphate (PO4) in order to prevent rickets.  
Worldwide, a few female cystinosis patients have had successful 
pregnancies, but there have been no reports of males cystinosis patients 
known to have the ability to cause pregnancy.  A study, in which seven 
male cystinosis patients (19-43 years) were treated with cysteamine, was 
carried out in order to analyse the fertility status in adults.99 
The findings of semen analysis performed on five patients displayed 
azoospermia, and the biopsy of one patient’s testis revealed 
spermatogenesis which may offer male cystinosis patients the prospect of 
producing their own progeny via in vitro fertilisation.99  
 
1.4.1. Cysteamine 
 
Currently the only treatment used to deplete cystine is the oral 
administration of cysteamine bitartrate (Cystagon®); the only commercially 
marketed drug for the treatment of cystinosis and has been used effectively 
since the 1970s.  
In the early 1980s, studies have shown that the introduction of cysteamine 
for the treatment of cystinosis has helped not only to reduce the decline in 
renal function but also to improve linear growth in diseased children even 
with a deficiency in renal tubule transport.35 As a result these patients have 
reached adulthood and even had children.21,100 
 
In 1987 a study involving 93 children treated with cysteamine was 
conducted in order to demonstrate and support these findings. The results 
were conclusive and demonstrated that cysteamine was also very effective 
at depleting intracellular cystine.94 
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In 1994, Cystagon® was also approved by the Food and Drug Administration 
in the USA.101 
Cysteamine also known as mercaptamine or β-mercaptoethylamine, MEA 
(c) occurs naturally from the breakdown of pantotheine (d) to pantothenic 
acid (e) and cysteamine which then undergoes oxidation by the enzyme 
cysteamine oxidase to produce hypotaurine (f).102 
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Cysteamine present as the bitartrate salt is a very stable, water-soluble 
drug available in capsules containing the equivalent of 50 mg or 150 mg of 
cysteamine free-base.101  The amino-thiol cysteamine works by lowering 
intracellular cysteine levels due to the formation of a disulfide bond between 
cysteamine and cysteine giving rise to a cysteamine-cysteine mixed 
disulfide.103 (Figure 11) The resulting compound is isosteric with lysine and 
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may egress the lysosome using the lysine transport protein which remains 
intact in cystinosis.103   Cysteamine-cysteine exits the lysosomes within a 
cell via the lysine excretion pathway hence, removing almost all the 
lysosomal cysteine from cystinotic cells.7,10,104  
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Figure 11.:  The mode of action by which cysteamine exists the           
                           lysosomes via the lysine transporter. 
 
 
Cysteamine has a half-life of 1.88 hours,105 reaching high blood level peaks 
at 1h, and a subsequent rapid decline.21 As a result of this a nightly oral 
dose should not be omitted, however, this can have an impact on the 
quality of life of both the patients and their families.100   
Studies have shown that cysteamine can also successfully deplete up to 
95% of cystine from cells in the kidneys, liver, pancreas, lung and spleen 104 
when compared to ascorbic acid (g)106,107 , penicillamine (h)108,109,110 and 
dithiothreitol (i).111  
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The ability for this drug to remove almost 90% of the cystine content from 
the cystinotic cells fails to prevent or reverse the Fanconi syndrome but 
reduces glomerular damage, and delays the onset of renal failure 
(ESRD)41,53 as well as the necessity for renal allograft 7,53.  In order to 
prevent renal failure, hypothyroidism and a host of non-renal complications, 
early lifelong and diligent cysteamine therapy should be considered 
immediately after diagnosis and should be initiated to all patients regardless 
of their age and transplantation status.7,53,105,112  
In cystinosis the treatment is only effective if cysteamine is frequently 
administered (every six hours) to children and adults in a capsule form and 
at a dose of 60-90mg/kg/day.  Adults can take a dose of 500mg every six 
hours and up to a maximum dose of 750mg.113 
 
In infants cysteamine is also given every six hours as a solution of 
cysteamine hydrochloride (K) at a dose of 50mg/ml.7 
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The regular use of cysteamine is also of a paramount importance as this will 
enhance growth as well as depleting cystine in muscle parenchyma. 
94,112,114,115   
Following an oral dose of cysteamine (5-6 hours) leucocyte cystine levels 
are measured so that they can be used to help evaluate the efficacy of the 
treatment and to establish appropriate dosing regimen.7 
Children with cystinosis who have received early and diligent treatment 
have demonstrated a development in their renal capacity up to age of 3 
years, and did not require renal transplantation. Increased life expectancy 
for up to 20 years has also been reported. 7,8  Moreover, the growth profile 
of the children has too been improved which gave a good incentive to the 
importance of an early provision of diagnosis and treatment as well as a 
regular and compliant regimen. 
Topical cysteamine hydrochloride eye drops have been used as an add on 
therapy and must be applied every 1 to 2 hours due to a very short 
residence time.116,117  Their  
use was first introduced in 1987 by both Gahl et al and Dufier et al.118,119  
This topical therapy is required to dissolve corneal crystals 30 and is usually 
initiated for school age children and has been proven effective in improving 
photophobia within few weeks of commencing the treatment.7,73 
 
1.4.2. Problems associated with cysteamine treatment 
 
One of the major problems associated with the administration of cysteamine 
is the extensive loss of the drug due to first-pass metabolism.  Cysteamine 
and can also be bound to circulating proteins preventing it from being 
absorbed.100,120 However, a successful treatment outcome will require high 
blood levels of cysteamine which can only be achieved by high doses of the 
administered drug.  In addition, the low molecular weight thiol has raised a 
number of pharmaceutical challenges because of its offensive taste, smell 
and a variety of unpleasant gastrointestinal (GI) side effects caused by a 
large production of gastric acid resulting in nausea, and vomiting which 
regularly occurs following drug ingestion.51,100,121,122,123,124  Loss of appetite 
has also being noted.51,121,122,123  
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Nausea is the most frequent side effect and can be successfully alleviated 
however, by the use of antiemetics and should be initiated as early as 
possible into the treatment. Other drugs such as H2 blockers or a proton 
pump inhibitor (PPI) have also been used to combat GI side effects.7,112 
Other problems associated with the treatment are the excretory pathways 
of cysteamine from the body which include the breath and sweat, resulting 
in halitosis and an unpleasant body odour.  In addition to the side effects of 
cysteamine and its malodorous metabolites (H2S, CH3SH), frequent 
administration (every 6 hours) of Cystagon® can impact upon patient 
compliance especially when patients reach adolescence.51 However, it has 
been reported that a third of cystinosis patients rigorously comply with this 
dosage regimen.7,112  
Unfortunately this treatment is not curative of the disease as it will 
progressively cause death due complications including, diabetes, and 
difficulties in swallowing, cardiovascular disease, muscular wasting and 
damage in both the cornea and retina but in most cases sepsis or 
respiratory problems will be the main cause of death.8,21,125,126   The 
development of these serious complications arises from cystine 
accumulation in various non-renal organs such as the eye, pancreas, liver, 
brain, thyroid, and muscles.  
Despite the difficulties that these patients face, their life expectancy has 
been improved however, and some even survive into their fifth decade of 
life with the ability to engage in a normal fulfilling lifestyle.35 
A continual cysteamine treatment is imperative post kidney transplant due 
to a build up of crystals in other tissues and organs 40,100, by host 
macrophages.  As a result of this overabundance in crystals, multiple organ 
systems are damaged, causing major complications including difficulty in 
swallowing occurring due to generalised muscular wasting, diabetes, and 
cardiovascular disease. Crystal overload in both the cornea and retina have 
also caused problematic complications to the patients especially to their 
quality of life.125,127,128    
Signs of cerebral deterioration were noted in patients reaching their 
twenties, displaying a mental decline, pyramidal signs and severe visual 
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memory loss but only for a short-term.40  Other symptoms include severe 
impairment of spatial processing functions.129 In addition, it has been 
reported that cystinosis patients are more likely to have a lower IQ than 
their parents and siblings.130  Academically, these patients experience 
difficulties, particularly in the areas of mathematic and spelling.131 
 
1.5. Pro-drug approach 
 
In order to overcome the problems associated with the oral administration 
of cysteamine, numerous studies have been undertaken, in which a number 
of cysteamine pro-drug derivatives have already been designed, 
synthesized and currently evaluated for their ability to deplete cysteine or 
cystine in cultured cystinotic cells.51  These pro-drugs work by masking the 
thiol functional group responsible for the unpleasant taste and smell of the 
drug, increasing the molecular weight of cysteamine thus reducing its 
volatility and also by improving its lipophilicity.  
An example of this type of studies was the one conducted by Gahl et al. in 
1988, when the pro-drug phosphocysteamine (l) was considered as a 
potential alternative to cysteamine.132  
 
 
                                             
                                                   (l)    
 
The study examined the comparison of a typical cysteamine treatment and 
phosphocysteamine. The findings showed that by masking the thiol group 
responsible for the offensive taste and smell, the side effects were reduced.  
An increase in bioavailability was also reported as a result of reduced 
protein binding.  It was suggested that the pro-drug phosphocysteamine 
becomes active by intracelluar dephosphorilation, thus directly targeting the 
lysosomal cystine stores.   In conclusion, this study demonstrated a degree 
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of similarity between cysteamine and the pro-drug in terms of treatment 
efficacy.                                                         
Pro-drugs are pharmacologically inactive compounds, converted in the body 
either spontaneously or by metabolic biotransformation to release the 
parent drug. This conversion is often carried out by enzyme-controlled 
metabolic reactions and can either occur before, during or after 
absorption.51  
Pro-drugs are extremely valuable composites to use when the parent drug 
is ineffective, toxic or defective at reaching its site of action.  In addition, 
enhanced efficacy and reduced toxicity can both be achieved by pro-drugs 
through control of absorption, blood levels, metabolism, distribution and 
cellular uptake. 
‘’Pro-drugs are designed to overcome pharmaceutically and/or 
pharmacokinetically based problems associated with the parent drug 
molecule that would otherwise limit the clinical usefulness of the drug.’’ 133 
The underlying principles of the pro-drug approach are to:134 
 
 Increase chemical or biological stability of a drug. 
 Reduce drug toxicity.  
 Make the drug more patient compatible by improving the taste. 
 Achieve site specific delivery. 
 Alleviate pain caused by parenteral administration of a drug. 
 Modify the length of the time of the drug’s duration of action. 
 Increase lipid or water solubility. 
 
Pro-drugs are broadly classified into two groups, namely, bioprecursor and 
carrier pro-drugs.  Bioprecursor pro-drugs are converted into their active 
compounds involving a variety of metabolic reactions including, oxidation, 
reduction and phosphorylation. Figures 12 and 14 illustrate a summary of 
the overall process. 
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Figure 12.: Bioprecursor Pro-drugs.134 
 
Levodopa (m) is an antiparkinsonian agent used in the treatment of 
Parkinson’s disease, a condition caused by a deficiency in Dopamine (n).  
This dopaminergic drug is a classic example of a bioprecursor pro-drug. 
Unlike levodopa dopamine is less likely to cross the blood-brain barrier 
(BBB) due to its insufficient lipophilicity.  Levodopa is more able to cross the 
BBB, not only because it is polar, but because it is an amino acid and able 
to be transported across the blood-brain barrier and into the site of action 
(brain) by amino acid transporters.  Subsequent enzymatic decarboxilation 
of levodopa will result in the release of active dopamine.135 (Figure 13) 
 
                    (m)                                                                                (n)                                                              
              Figure 13.: Metabolic pathway for Dopamine formation 
 
Carrier pro-drugs differ from bioprecursor pro-drugs in that they are formed 
by combining an active drug with a carrier species creating a compound 
with the desired chemical and biological characteristics.134   (Figure 14) 
 
BIOPRECURSOR Drug 
In vivo generation 
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                                           Figure 14.:  Carrier Pro-drugs  
 
 
Ideally all carrier pro-drugs should: 134 
 
 Be less toxic than the patent drug.  
 Have an improved bioavailability when orally administered. 
 Be site specific. 
 Be inactive or significantly less active than the parent drug. 
 Have a rate of drug formation rapid enough to maintain the drug’s 
concentration within its therapeutic window. 
 
The pro-drug concept has been adopted for a number of years and in 
various therapeutic areas such as in the treatment of ulcers, antibiotics and 
antihistamines.51   A study by Nolen et al. demonstrated a typical example of 
such therapy which involved the pro-drug Budesonide-beta-D-glucuronide 
used orally for the potential treatment of colonic inflammatory bowel 
disease. The management of this condition which usually involves the use of 
budesonide, a topically active glucocorticosteroid with low oral 
bioavailability (15%), is substituted by the oral administration of 
glucuronide pro-drug and should provide localised high concentration of the 
active drug.  Once the parent drug budesonide has been delivered and 
absorbed, inactivation of the large fraction should be expected owing to 
hepatic metabolism.136 
Antibiotic therapy is another area where wide arrays of pro-drugs have been 
used to afford a better bioavailability, minimise toxicity or to resolve 
organoleptic problems associated with certain drugs.137   
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Ampicillin (o) is a broad spectrum antibiotic used for the treatment of a 
wide range of infections such as urinary-tract-infections (UTIs), otitis media, 
sinusis, oral infections and many more.  Despite ampicillin’s large 
bactericidal activity and reduced toxicity, only 30% to 50% is absorbed in 
the gut.137   Bacampicillin (p), displays a greater bioavailability (95%) than 
the parent Ampicillin.  An average oral dose of 400mg of Bacampicillin will 
achieve a high plasma concentration of 7µg/ml which is equivalent to 
1000mg of Ampicillin.  As a result of these pharmacokinetic characteristics, 
Bacampicillin plasma concentration can be rapid and elevated when 
compared to the one achieved from the same doses of the parent drug.  
Furthermore, only 18% of the pro-drug is bound to plasma proteins allowing 
a high concentration of free and therapeutically active Ampicillin.137 
 
  
 
 
44 
 
H
N
NH2
O
O
N
S
O
OO
O
O
BACAMPICILLIN
H
N
NH2
O
O
N
S
O
OO
+ CH3CH2OH  + CO2
E
S
T
E
R
A
S
ES
H
N
NH2
O
O
N
S
OH
O
SPONTANEOUS
H
O
+
AMPICILLIN
(p)
(o)  
                                     
                      Figure 15.:  Activation of Bacampicillin 
 
This sophisticated approach has been considered, because it demonstrates 
both the enhanced pharmacodynamic and pharmacokinetic properties of the 
pro-drug, when compared to the parent drug. These properties encompass 
the most favourable interaction of the pro-drug with the target, and the 
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improvement of the drug’s ability to reach its target and to have an 
acceptable lifetime.134 (i.e. make the molecule more ‘druggable’). 
Besides the uses and effectiveness of pro-drugs in other diseases, they are 
also being investigated for the treatment of cystinosis.  As part of the work 
carried out to improve the treatment of this genetic disease, three 
generations of cysteamine and cystamine pro-drugs derivatives have been 
synthesised and biologically evaluated by a team of researchers based at 
Robert Gordon University.   
Fatty amide derivatives of cystamine (q) were the first generation pro-
drugs to be synthesised.138 (Figure 16) 
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Where n= 7-15 
                 Figure 16.:   Fatty amide derivatives of cystamine                     
 
The second generation of pro-drugs were the PEGylated pro-drugs (Figure 
17) derived from the activation of their carboxylate terminals with excess 
carbonyldiimidazole (CDI), followed by a coupling with amino 
polyethylenglycol. These compounds were synthesised with acceptable 
yields 40%-60%.139 
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Where n= 2                                                                                                                                                                                                        
                        Figure 17.:   PEGylated Pro-drugs                                                   
 
The third generation of pro-drugs were synthesised using a route 
established in our laboratories.  Briefly, cystamine dihydrochloride the 
disulfide derivative of cysteamine was basified and allowed to react with a 
number of cyclic anhydrides under basic conditions. The resulting di-acids 
were reacted with carbonyldiimidazole (CDI) and monoBoc-cystamine to 
yield the desired pro-drugs.  Removal of the tBoc-protecting group was 
achieved in a facile manner by use of trifluoroacetic acid (TFA).140 (Figure 
18).    
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              Figure 18.:  Succinic and Glutaric Cystamine Pro-drugs Derivatives                             
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Additionally a folate pro-drug derivative of cystamine was also synthesised 
(Figure 19).  This new pro-drug was non cytotoxic and displayed the 
greatest ability to reduce intralysosomal cystine seen so far in our studies, 
when compared to previous pro-drugs.141 
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Figure 19.:  Chemical synthesis of the Folate Pro-drug Derivative of Cystamine. 
Reagents and Conditions: (i) tert-butyl 2-(2-(aminoethyl) disulfanyl) 
ethylcarbamate (2.5 equiv), DEC (4 equiv), 12h, rt.  (ii) 4 N HCl in dioxan, 30 min, 
rt.  
 
 
Further work on pro-drugs has also been carried out by a team of 
researchers at the University of Sunderland and generated a group of pro-
drug involving the derivatisation of both the amino and thiol functional 
group responsible for the unpleasant taste and smell of cysteamine.  By 
developing γ-glutamyl pro-drug derivatives the properties of the parent 
drug (cysteamine) are altered and the problems of taste and smell reduced 
to negligible levels. 
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These pro-drugs are known to resist proteolytic degradation and can only be 
hydrolysed in the presence of the enzyme gamma-glutamyl transpeptidase 
(GGT) which is specific to γ-glutamyl pro-drugs. 
GGT is required for the glutathione cycle and can be found in high 
concentrations on the surface of most cells including the kidney, liver, skin, 
and pancreas, allowing it to interact with -glutamyl-cysteamine pro-drugs.  
This in turn will result in the intracellular release of both glutamate and 
cysteamine.142 
 
To date, the work in pro-drugs has been fruitful and generated a 
considerable number of non cytotoxic compounds which displayed 
significantly greater ability to deplete the level of intralysosomal cystine in 
cultured cells when compared to the parent drug.  The advantages of using 
cysteamine pro-drugs in the treatment of cystinosis are three fold, namely 
masking the unpleasant taste and smell, achieving desirable kinetics by 
avoiding release during passage through the gut and thus reducing the 
frequency of drug administration and finally efficient and complete release 
of multiple molecules of cysteamine (up to six molecules) once in the blood. 
With this approach patient compliance will be enhanced leading to an 
improved quality of life.51,140,141,143 
 
       1.6. Research Progress 
 
Recent advances have demonstrated that kidney function can be saved if 
early diagnosis and initiation of a diligent cysteamine therapy are 
undertaken.  The earlier patients receive treatment ideally before the age of 
2 years the more likely they will be to retain their kidney function.   
Comencement of early cysteamine therapy also reduces the chances of 
developing cystinosis – related complications at a later age.21 
 
In 1998 it was reported that cysteamine should not be recommended during 
pregnancy and breastfeeding due to its teratogenic and fetotoxic effects.105 
These studies have shown that these side effects are linked to the 
production of hydroxyl radicals.144 Therefore, treatment with cysteamine 
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should be suspended during the period of gestation and nursing.  However, 
in order to prevent ill health, advice should be given to those wishing to 
conceive about the potential risks associated when stopping cysteamine 
therapy.  
Other recent studies have reported a new side effect on the elbow and 
knees (Figure 20).  The reports describe the side effect as lesions similar to 
Ehlers-Danlos syndrome occurring due to high doses cysteamine resulting 
from altering a typical four times a day regime to larger doses of three 
times daily.  This treatment regimen is purposely used by patients to suit 
their daily routine.145 Nevertheless the symptoms can be alleviated by a 
dose reduction. 
 
                     
 
                 Figure 20.: Skin manifestations of cysteamine toxicity.146 
 
 
A group of researchers at King’s College in London have engineered a drug 
solution for use in renal transplantation.  It has been anticipated that this 
novel drug will help increase graft survival time 147 as well as maintaining 
effective kidney function during transfer from donor to recipient.  The 
launch of this drug solution is scheduled for 2015.147 
 
In the world of formulation, topical cysteamine treatment has been 
dramatically improved by the development of a bioadhesive ophthalmic gel 
which could potentially replace the current eye drops, thus reducing the 
frequency of administration from 10-14 times a day to twice or even once 
daily.  The novel gel has been formulated to slowly release the drug owing 
to its pseudoplastic property allowing a longer and painless (neutral pH) 
retention time when compared to the current eye drops.  
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The impermeable nature of the eye allows only 1% of cysteamine dose to 
reach the site of action (cornea) when used in the form of eye drops.  
Cysteamine eye drops have shown to clear crystals entirely from the cornea 
but only for a short time period, as result a multi-dose (15 times/day) is 
necessary.  This innovative product will not only improve compliance 
amongst cystinosis patients but will also prevent ophthalmic morbidity such 
as blindness.148 
Further formulation research resulted in 2013, in the launch of a new 
enteric coated formula of cysteamine bitartrate (trade name Procysbi™, 
Raptor Pharmaceutical Corp, USA).   This product was designed to reduce 
the number of cysteamine administration (every 6 hours) to only twice a 
day.149 
As previously mentioned, frequent administration of cysteamine is 
necessary in order to maintain White Blood Cells (WBC) cystine levels below 
1.0 nmol ½ cystine/mg protein.150  This new formulation has been designed 
so that the drug (cysteamine) can be administered directly into the small 
intestine resulting in increased plasma levels.151 
Recent clinical trials, in which a sequential treatment with Cystagon® and 
Procysbi™ was offered to patients for a period of 3 weeks gave clear 
evidence that Procysbi™ displayed similar efficacy in lowering WBC cystine 
levels when compared to Cystagon®.152  A safety extension study is 
currently underway.  
 
1.7. Aims of Project  
 
In an attempt to overcome the problems of palatability and the GI related 
side effects associated with the administration of cysteamine, the aim of 
this project was to synthesise, characterise and biologically evaluate a 
series of novel odourless and tasteless oral therapies for cystinosis.   It is 
anticipated that these compounds would enhance patient compliance 
resulting in an improved quality of life.  
Two approaches were adopted, the synthesis, characterisation and 
evaluation of novel pro-drugs of cysteamine and cystamine and the 
attempted synthesis of novel co-crystal forms of cysteamine and cystamine. 
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This study was undertaken to complement and further previous studies on 
pro-drugs 140 and focused on the synthesis of a small library of novel 
cystamine pro-drugs derivatives based on synthetic methods developed in 
house and pioneered by Omran et al. 2011. 
These compounds will be evaluated in vitro using human cystinotic 
fibroblasts (GM00008), to help establish a structure-activity relationship and 
to determine the biological activity of the new pro-drugs on cellular uptake 
and distribution.  It is hoped that these compounds will display significantly 
greater efficacy than cysteamine.    
In addition, both solid phase peptide synthesis (SPPS) and convergent 
peptide synthesis (CPS) techniques will be employed to generate a number 
of “pseudo-peptides pro-drugs”.  The new compounds will be composed of 
repeating units of cystamine with succinic and glutaric acids. 
 
Cell culture techniques developed in house will be used to evaluate both the 
cytotoxicity and the efficacy of the novel compounds. 
Finally, as part of our expanded synthetic work and our desire to produce 
odourless and tasteless oral therapies for cystinosis, there may be the 
possibility of the manufacture of co-crystals of cysteamine and cystamine.  
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CHAPTER 2 
MULTICOMPONENT CRYSTALS 
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2.1.     Multicomponent Crystals 
 
2.1.1.    Introduction 
The concept of multicomponent crystals has been adopted for a number of 
years and in 1844 a Quinhydrone prototype was first reported.153   
Co-crystals have been broadly defined as mixed crystals or crystals 
comprising of two different molecules.154,155,156  
Desiraju described the concept as “the understanding of intermolecular 
interactions in the context of crystal packing and the utilisation of such 
understanding in the design of new solids with desired physical and 
chemical properties”.157    
In 1955 Pepnisky established the hypothesis of crystal engineering.153   
The creation of a supramolecular assembly can be achieved through crystal 
engineering which involves using design to generate crystals.155  The 
concept of supramolecular synthesis or crystal engineering, aims to form 
new molecules in a solid state without breaking or forming covalent 
bonds.154   
Crystal engineering facilitates the study of the way molecules are packed 
together in the crystal lattice where intermolecular interactions are directed 
by hydrogen bonding.153  
Due to advances in technology, crystal engineering became a commonly 
used technique in the pharmaceutical industry.155  
This approach has also been applied to improve the pharmacokinetic 
properties of weakly soluble drugs without altering the stability of their 
physicochemical properties. 156,157 
On the basis of intermolecular interactions, crystal engineering aims to 
create unfailing links between molecular and supramolecular structure.157,158  
Polymorphism has been studied for a number of years and was first 
described in 1965 by McCrone, as “solid crystalline phase of a given 
compound resulting from the possibility of at least two different 
arrangements of the molecules of that compound in the solid state”.153  The 
same molecule can display different polymorphs (Figure 21) resulting in 
different solubility and melting points, and an example is that of the 
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barbiturates where 70% are present in various polymorphic forms with the 
most stable one exhibiting the lowest free energy.159,160  
 
 
 
Figure 21.:  Multiple polymorphic forms generated from the same molecule. 160 
 
In order to determine if hydrogen bonding has occurred, the study of the 
Lewis structure of a molecule must be carried out. Hydrogen bonding occurs 
between hydrogen atoms and electronegative atoms such as oxygen or 
nitrogen. This occurs due to an excess in electron density around the 
electronegative species.158    
Hydrogen bonds between OH...N and CH...O with energies of 2-20 kJmol-1 
are termed weak bonds, whereas bonds between OH....O and NH....O with 
energies of 20-40 kJmol-1 are termed strong bonds.161   
The bond length between a hydrogen donor (D) and an acceptor (A) is 
between 1.80 Å to 2.00Å for NH....O bonds, and between 1.60 Å to 1.80 Å 
for OH....O bonds.161 
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Multicomponent crystals are formed when intermolecular interactions take 
place between two or more components and these can be molecules, atoms 
or ions.162   Co-crystals, salts, solvates, hydrates and clathrates are types of 
multi-components crystals 163,164 as shown in Figure 22. 
 
 
 
 
 
Figure 22.:  Types of multicomponent crystals.164  
 
Salts form due to a proton transfer between an acid and a base 158 and are 
commonly manufactured with most active pharmaceutical compounds, 
usually to increase aqueous solubility or to provide a stable, crystalline 
species for formulation.165 
To produce a stable salt the pKa of each component should vary by at least 
two (log) units.166   pKa is a term used to express the strengths of acids and 
bases and is defined as the negative logarithm, to the base 10, of the 
dissociation or ionisation constant.  Solvates occur if one of the components 
is a liquid at room temperature.154 Hydrates arise when water has been 
incorporated into the crystal structure.167  
Co-crystals have been described as crystalline materials consisting of two or 
more components that are solids at ambient temperature held together in a 
crystal lattice via hydrogen bonds.168,169  This is shown in Figure 23.170 
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 Figure 23.:  Non-covalent bonds between the drugs Lamivudine and 
Zidovudine.170  
 
 
In contrast to salts, there is no proton transfer taking place between the 
constituents of a co-crystal.165  
The design of co-crystals has been based on the crystal engineering 
approach which provides an insight on the molecular interactions between 
functional groups in particular hydrogen bonding interactions.171 
The recent advances in the area of drug formulation enabled the 
opportunity to manufacture pharmaceutical materials by design.  
Particularly, the development of co-crystals symbolises a prospective way to 
produce pharmaceutical compounds with improved physicochemical 
properties of interest.171,172, 173   
Indeed, these properties are of paramount importance for the safe, efficient 
and cost-effective delivery of a drug to a patient, as schematically 
illustrated in Figure 24.172  
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Figure 24.:  Properties vital for a successful drug candidate.
172 
 
 
Crystal engineering or supramolecular synthesis aims to produce 
pharmaceutical co-crystals in the form of a supramolecular synthon.174 This 
process is aided by the presence of carboxylic acid functional groups which 
represent a good foundation for the process of crystal engineering of 
pharmaceutical co-crystals.174 
Figure (25) represents the creation of a supramolecular homosynthon 
favoured by complementary carboxylic acid hydrogen bond donor and 
acceptor sites.153 
 
O
O
H O
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Supramolecular Homosynthrom  
 
Figure 25.:  Supramolecular Homosynthon. 
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A number of factors such as functional group position, geometry, and steric 
hindrance can control the process of co-crystallisation.   
Subsequently, a chemical structure on its own does not represent the sole 
basis of co-crystal formation.171  
The most commonly used method in co-crystallisation is the slow 
evaporation technique which requires a solvent.  To prevent solvates 
forming, the grinding method whereby the solvent is omitted is often 
employed as the method of choice. (Figure 26)  
 
 
 
Figure 26.:  Crystallisation of single crystals by the process of grinding.175 
 
This method simply involves two solid starting materials placed in a ballmill.  
However, this solid state approach results in the reduction of the particle 
size of the solid making the product unsuitable for structure elucidation by 
single crystal diffraction.168 
Other methods of co-crystallisation include; sublimation, slurries, and 
growth from melt.155  
 
As stated in the introduction, the objectives of the present work are to 
develop colourless and tastless oral therapies for Nephropathic Cystinosis. 
It was envisaged that co-crystals of cysteamne or cystamine with 
biologically acceptable organic acids provide a solution to this problem.  
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2.2.     Materials and Instrumentation 
 
2.2.1.   Materials 
One-step chemical reactions were performed with laboratory grade reagents 
purchased from Sigma-Aldrich, UK unless otherwise stated, and were used 
without further purification.  
 
2.2.2.    Instrumentation 
A Metler AE 240-S analytical balance was used to record the weights of 
products. 
The chemical structure and purity of the products were determined by 
Melting Point (MP), Differential Scanning Calorimetry (DSC), Fourier 
Transform Infra-Red (FTIR), and Single-Crystal X-Ray Diffraction. 
The melting points were determined on a Stuart Scientific SMP1 apparatus 
and are uncorrected.  The Infra-Red (IR) spectra were recorded on a Nicolet 
Avatar 360 FTIR and Nuclear Magnetic Resonance (NMR) spectra were 
obtained from a Bruker 400 ultarshield using Dimethyl Sulfoxide-d6 (DMSO-
d6) as solvent.   
 
2.3.     Methods 
2.3.1.   Slow Evaporation Technique 
2.3.1.a. General Preparation Method for Cystamine Adipate, Cystamine 2,6-
Dihydroxybenzoate, Cystamine Glutarate, and Cystamine 3-Nitrobenzoate from 
cysteamine. 
Millimolar amounts (1:1) ratio of cysteamine and each co-former were 
weighed.  Both materials were transferred to a 25 ml conical flask and 5 ml 
of hot ethanol was added.  The flask containing the mixture was then placed 
on a water bath at a temperature of 50°C and small aliquots of solvent were 
added until a clear solution was obtained.   The solution was then filtered, 
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loosely covered with parafilm and left in the fume cupboard to allow 
crystallisation to occur by slow evaporation.   
Following a few days, crystals formed.   These were collected by gravity 
filtration and allowed to dry on a filter paper. 
2.3.1.b. General Preparation of Cysteamine Bitartrate Monohydrate (Cysteamine 
Hydrogen Tartrate) [1] from Cysteamine. 
 
Millimolar amounts (1:1) ratio of cysteamine and L-(+)-tartaric acid were 
weighed and transferred into a 50 ml conical flask. A small amount (5 ml) of 
hot ethanol was added to the mixture, and the flask and contents were 
placed in a water bath, with swirling, at 50˚C. After 10 minutes (min) both 
starting materials remained solid, and so to aid dissolution the flask was 
stirred and heated to 60˚C on a hot plate. Further quantities of solvent 
were added drop-wise to the mixture until a clear solution was obtained. 
The whole process lasted for about an hour and a total volume of 15 ml of 
ethanol was used. The solution was then filtered, loosely covered with 
Parafilm and left in the fume cupboard for crystallization to take place by 
slow evaporation. After 5 days, clear rod shaped crystals of (I) separated 
from the product mixture. The crystals were then collected by gravity 
filtration and allowed to dry on filter paper. 
2.3.1.c. General Preparation of Cystamine Tartrate [2] and Cystamine Bitartrate 
Dihydrate (Cystamine Hydrogen Tartrate Dihydrate) [3] from cystamine. 
For [2] and [3] same millimolar amounts (1:1) ratio of cystamine and L-
(+)-tartaric acid were weighed and transferred into a 50 ml conical flask.  5 
ml of hot ethanol was added which resulted in the formation of a white 
precipitate. The flask was then placed in a 50°C water bath with swirling.  
Small aliquots of solvent were added drop wise until a clear solution was 
achieved.  A total volume of 20ml of ethanol was used.  The solution was 
then filtered, loosely covered with parafilm and left in the fume cupboard for 
crystallization to take place by slow evaporation. The following day crystals 
were formed.  
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The crystals (blades [2] and needles [3]) were then collected by gravity 
filtration and allowed to dry on a filter paper.   
Product [3] also formed as a non-crystalline mass in the preparation of 
product [1]. Attempts to obtain high quality crystals of product [3] were 
only partially successful. 
2.3.2.    Melting Point Determination 
Prior to undertaking slow evaporation, the Stuart Scientific SMP1 apparatus 
was used to record the melting point of each starting material.  The melting 
point was recorded from the start of phase change and until complete 
liquification of the sample.  The same procedure was also carried out for all 
crystalline products. 
2.3.3.    Differential Scanning Calorimetry (DSC) 
Approximately 5mg of the sample to be analysed was weighed using the 
Metler AE50 balance, and hermetically sealed with an aluminium lid.  The 
Universal Analysis Software was used to process all the results. 
2.3.4.    Infra-Red (IR) Spectroscopy 
     An IR spectrum was collected for all starting materials prior to commencing 
crystal preparation. A small amount of the sample to be analysed was 
placed directly into contact with the diamond point after which all generated 
spectra including the ones from the newly formed crystals were analysed 
using OMNIC software (Trademark of Nicolet Instrument Corporation, 
Madisson, U.S.A.).  A comparison of all spectra was then achieved.  The 
diamond accessory was the method of choice as it only required a small 
amount of the sample to be analysed.  Additionally, a dried mixture of 
Potassium Bromide (KBr) and the sample was used to achieve a better 
quality spectrum. 
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2.3.5.    X- Ray Crystallography  
The collection of X-Ray data for the newly synthesised crystals was carried 
out by the Engineering and Physical Sciences Research Council (EPSRC) 
National X-Ray Crystallography Service at Southampton University. 75  
The WingGX system was used to solve, refine and analyse the molecular 
structure. 76 
Hydrogen bond acceptors and donors of acid co-formers were obtained with 
the Marvin computer software.85   (Table 2) 
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       Table 2.:   Hydrogen bond acceptors and donors 
Compound  Structure Number of 
hydrogen donors/ 
acceptors 
Adipic acid 
 
Donor sites :       2 
 
Donor count:       2 
 
Acceptor sites:    6 
 
Acceptor count:   4 
3 - Nitrobenzoic acid 
 
Donor sites :       2 
 
Donor count:       2 
 
Acceptor sites:    6 
 
Acceptor count:   4 
2, 6 – Dihydroxybenzoic 
acid 
 
 
Donor sites :       3 
 
Donor count:       3 
 
Acceptor sites:    5  
 
Acceptor count:   4 
 
Glutaric acid 
 
 
 
 
Donor sites :       2 
 
Donor count:       2 
 
Acceptor sites:    6 
 
Acceptor count:   4 
L (+)- Tartaric acid 
 
Donor sites :       4 
 
Donor count:       4 
 
Acceptor sites:    8 
 
Acceptor count:   6 
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3.1. Synthesis of Novel Cystamine Pro-drug Derivatives 
 
In this chapter the aim of the experimental work was to synthesise and 
characterise a small library of cystamine derivatives using a number of 
dicarboxylic acids.   
 
 3.1.2.     Materials 
    
All chemicals were purchased from Sigma Aldrich, UK unless otherwise 
stated, and were used without further purification. 
Silica gel 60 F254 gel……………………………………………….Merck (Germany) 
Dimethyl Sulfoxide-D6 (DMSO-d6)……………………..Goss Scientific (UK) 
Dichloromethane (DCM)…………………………………………Fisher Scientific (UK) 
Chloroform (CHCl3)…………………………………………………Fisher Scientific (UK) 
Dimethylformamide (DMF)…………………………………….Fisher Scientific (UK) 
 
3.1.2.1.   Instrumentation 
Thin layer chromatography (TLC) was performed on silica gel 60 F254 
Aluminium plates (2cm x 5cm) (Merck, Germany) in a mobile phase of 
ethylacetate:methanol (1:1 or 9:1) mobile phase.  Spots were visualized 
with short wavelength UV-light (254 nm) or if no chromophore was 
present, with iodine vapour. 
TLC determination involved a stationary phase consisting of a silica gel 
aluminium plate onto which a small spot of the reaction mixture was 
spotted using a micro pipette.   The silica plate was allowed to dry, and 
subsequently placed vertically in a TLC development tank containing the 
solvent as the mobile phase.  This system allows the solvent to travel by 
capillary action which separates the mixture into distinct spots 
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corresponding to the components contained within the solution.  Once the 
plate is dry, the spots are visualised under UV-light. 
Mass spectra were obtained on a Thermofisher LTQ orbitrap XL (low 
resolution) mass spectrometer. MS works on the basic principle of 
generating and separating charged molecules according to their mass-to-
charge ratio (m/z) defined as the charge of an anion using an electric 
and/or magnetic field. 
ESI allows the production of negatively charged ions through atomisation.  
These fragments are then accelerated, detected and translated into a 
mass spectrum.179 
Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker 
400 ultrashield spectrometer operating at 400.1 MHz for proton (1H).  
Samples were dissolved in DMSO-d6. 
Wilmad 5 mm Economy NMR Tubes (N51 glass, WG-1228-8) were 
purchased from Goss Scientific Ltd, UK. The NMR solvent, Dimethyl 
Sulfoxide-D6 (DMSO-d6) was used for analysis of both intermediate and 
final compounds. The compounds obtained from the synthetic process 
were concentrated, dried and residual solvent removed.  The samples 
were subsequently dissolved in an appropriate deuterated solvent, such as 
Dimethyl Sulfoxide-D6 (DMSO-d6).  Approximately 1-2 ml of the sample 
were transferred to a NMR tube, capped and introduced into the NMR 
instrument.  Once the sample was lowered into the NMR probe, it 
underwent rotation, locking and shimming, before being processed by the 
Bruker Topspin 1.3 software, to give an NMR spectrum.   
Magnetic resonance occurs due to magnetic properties exhibited by 
specific nuclei, in particular, proton (1H or hydrogen).  1H NMR can be 
viewed at frequency of 400.1.  Protons can be detected by 1H NMR. 
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3.1.3.        Methods 
 
3.1.3.1.     Synthesis of Cystamine Pro-drugs Derivatives 
 
Mono-Boc-Cystamine (starting material) was prepared from cystamine 
dihydrochloride (5g; 22mmol) dissolved in dH2O (10 mL).  The resulting 
solution was basified with NaOH to pH 14.  Cystamine free base (2.25g; 
15mmol) was dissolved in chloroform (10mL) at 0˚C and a solution of Di-
ter-Butyl dicarbonate (Boc)2O (1.09g; 5mmol) in 50mL CHCl3 added drop 
wise over three hours.  The reaction mixture was stirred at room 
temperature for a further 12 hours.  The resulting product was extracted 
with DCM, dried over MgSO4 to afford a yellow solid.   
This was purified by flash chromatography (elution with 90% DCM/MeOH) 
and 1% NH4OH to yield a yellow oil.
180  
Boc-Cystamine (0.38g; 30%).  LR-MS for C9H20N2O2S2 [Mass: 252], found: 253 
(M + H+) (100%), 375 (M + Na+) (20%).   
1H NMR (400 MHz, DMSO-d6) δ (ppm): 1.45 (s, 9H, CH3), 1.55 (s, NH2), 2.77 (t, 
2H, CH2S), 2.79 (t, 2H, CH2S), 3.02 (t, 2H, CH2NH2), 3.44 and 3.46 (2t, 2H, 
CHHNHBoc), 4.95 (s, NH). 
 
3.1.3.1.1.       Synthesis of Pro-drug Cystamine - Succinate 
[2-(2-{4-[2-(2-{4-[2-(2-tert-Butoxycarbonylaminoethyldisulfanyl)-ethylcarbamoyl]-
propionylamino}-ethyldisulfanyl)-ethylcarbamoyl]-propionyllamino}-ethyldisulfanyl)-ethyl]-
carbamic acid-tert-butyl ester. (1) 
Compound 1 was synthesised from intermediates (2) and (3) as described 
in sections 3.1.3.1.1.a. and 3.1.3.1.1.b. respectively.  
 
(1) (1.94g; 83%), LR-MS for C30H56N6O8S6 [Mass: 820], found: 821 (M + H
+) 
(100%), 843 (M + Na+) (10%), 865 (M + FA – H+) (100%). 
1H NMR (400 MHz, DMSO-d6) δ (ppm): 1.37 (s, 18H, CH3), 2.30 (s, 8H, BocCH2), 
2.74(t, 12H, COCH2CH2), 3.19 (t, 4H, CH2CH2S), 3.30(m, 8H, CH2CH2NH), 6.99(t, 
2H, NH2CH2), 8.04 (t, 4H, CH2NHCO).  Figure A.1; Appendix 2 
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3.1.3.1.1.a.   Synthesis of N,N’-Disuccinoylcystamine - Diamide (A) 
N-{2-[2-(3-Carboxy-propionylamino)-ethyldisulfanyl]-ethyl}-succinamicacid. (2) 
 
Cystamine dihydrochloride (1.0g; 44mmol) was dissolved in 150 mL of 
distilled water (dH2O).  The resulting solution was basified with 4M NaOH 
to pH 10.  To this solution (3.33g; 132.9 mmol) of succinic acid anhydride 
were added, and the pH maintained between 7 and 10 with additional 
NaOH.  The solution was stirred for 30 minutes, at room temperature, 
then the pH was reduced to 1 by addition of 6M hydrochloric acid (HCl), 
whereupon, a white precipitate formed.  The latter was carefully washed 
with distilled water (200 mL) and dried under reduced pressure. 
(2) (0.456g; 92%), mp 162˚C - 164˚C.  
LC-MS for C12H21N2O6S2 [Mass: 352], found: 353 (M + H
+) (100%).  Other major 
peaks 375 (M +Na+) (75%), 351 (M + Cl-) (100%). 
1H NMR (400 MHz, DMSO-d6) δ (ppm): 1.65 (t, 2H, CH2CH2CO); 2.30 (t, 2H, 
COCH2CH2); 2.42 (t, 2H, CH2CH2S); 2.72 (m, 2H, NHCH2CH2); 8.0 (t, 2H, 
CH2NHCO); 9.2 (s, 1H, CH2COOH). Figure A.2; Appendix 2 
 
3.1.3.1.1.b.       Synthesis of the Imidazolide Derivative  
[2-(2-{4-[2-(2-{4-[2-(2-tert-Butoxycarbonylaminoethyldisulfanyl)-ethylcarbamoyl]-
propionylamino}-ethyldisulfanyl)-ethylcarbamoyl]-propionyllamino}-ethyldisulfanyl)-ethyl]-
carbamicacid-tert-butyl ester.  (3) 
 
To a solution of N, N’-disuccinoylcystamine (1.0 g; 2.8 mmol) in 10 mL of 
anhydrous DMF, was added CDI (1.05 g; 6.5 mmol) resulting in a rapid 
formation of a white precipitate. The reaction mixture was stirred at room 
temperature for 3 hours, after which time a small aliquot was used for 
analysis, and a solution of mono-substituted cystamine (1.13g; 4.5mmol) 
in 5 mL of anhydrous DMF was added, without isolating the product 
intermediate (3).  The reaction mixture was stirred for a further 12 hours, 
at room temperature.  Following solvent evaporation, 25 mL of distilled 
water was added to the residue and the white precipitate (compound 1) 
was then filtered off, washed with small amounts of aqueous 0.1M HCl and 
ethylacetate, then dried in vacuo at 70oC. 
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 (3)-crude LR-MS for C18H24N6O4S2 [Mass: 452], found: 453 (M + H
+). 
 
3.1.3.1.1.c.  Deprotection of compound (1) N1,N1'-(disulfanediylbis(ethane-
2,1-diyl))bis(N4-(2-((2-aminoethyl)disulfanyl)ethyl)succinamide). (4) 
 
Compound 1 (0.5g; 0.6mmol) was dissolved in 5 mL of trifluoroacetic acid, 
and the solution was stirred for 30 minutes at room temperature, after 
which ethanol (20 mL) was added (i).    
The solution was allowed to stand for 15 minutes at room temperature (ii) 
then residual solvent was evaporated using the rotary evaporator (iii). 
Steps (i-iii) were repeated 3 times.   To the resulting solution, 5 mL of 
diethyl ether was added to give a white precipitate (compound 4).  This 
was collected by filtration and dried at 50o C, under vacuo. 
 
(4) (0.36g; 72%), LR-MS for C20H40N6O4S6 [Mass: 621], found: 623 (M + 2H
+) 
(15%).   Other major peak, 311 (M +2H)/2 (100%). 
1H NMR (400 MHz, DMSO-d6)   δ (ppm): 2.31 (s, 8H, NH2CO), 2.76 (m, 4H, 
BocCH2CH2), 2.94 (t, 8H, COCH2CH2), 3.11(t, 4H, CH2CH2S), 3.31(m, 8H, 
NHCH2CH2), 8.11(t, 10H, CH2NHCO).   
 
 
 3.1.3.1.2.       Synthesis of Pro-drug Cystamine Glutarate  
[2-(2-{4-[2-(2-{4-[2-(2-tert-Butoxycarbonylamino-ethyldisulfanyl)-ethylcarbamoyl]-
butyrylamino}-ethyldisulfanyl)-ethylcarbamoyl]-butyrylamino}-ethyldisulfanyl)-ethyl]-
carbamic acid tertbutyl ester. (5)  
 
This compound was prepared using the method for compound 1. 
 
(5) (1.64g; 73%), LR-MS for C32H60N6O8S6 [Mass: 848], found: 849 (M + H
+) 
(35%), 871 (M + Na+) (100%), 883 (M + Cl-) (100%), 893 (M + FA – H) (40%).  
Other peaks of interest; 619 (M/2 + 2tboc) (40%). 
 1H NMR (400 MHz, DMSO-d6) δ (ppm): 1.36 (s, 18H, CH3); 1.77 (m, 4H, 
CH2CH2CH2) 2.12 (t, 12H, COCH2CH2), 2.80(m, 4H, NHCH2CH2), 3.20(t, 8H, 
CH2CH2S), 3.38(m, 8H, NHCH2CH2S), 7.07- 8.20 (t, 6H, CONHCH2).  Figure A.3;   
Appendix 2 
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3.1.3.1.2.a.    Synthesis of N,N’-Diglutaroylcystamine - Diamide (B) 
5,5'-((disulfanediylbis(ethane-2,1-diyl))bis(azanediyl))bis(5-oxopentanoic acid). (6) 
 
This compound was prepared from glutaric anhydride (1.53g; 13.42mmol) 
using the method for diamide A. 
 
(6) (1.34g; 90%), mp 121˚C - 128˚C. LR-MS for C14H24N2O6S2 [M: 380], found: 
381 (M + H+) (45%), 403 (M + Na+) (100%), 379 (M – H+) (100%).  
1H NMR (400 MHz, DMSO-d6) δ (ppm): 1.69 (m, 2H, CH2CH2CH2); 2.10 (t, 2H, 
CH2CH2CO); 2.22 (t, 2H, CH2CH2COOH); 2.73 (t, 2H, CH2CH2S); 3.28 (q, 2H, 
NHCH2CH2); 8.0 (t, 2H, CH2CONH). Figure A.4; Appendix 2 
 
 
3.1.3.1.2.b.     Synthesis of the Imidazolide Derivative  
N,N'-(disulfanediylbis(ethane-2,1-diyl))bis(5-(1H-imidazol-1-yl)-5-oxopentanamide). (7) 
 
This compound was prepared from N,N’-diglutaroylcystamine (1.0 g, 2.6 
mmol) using the method described in section 3.1.3.1.1.b.      
          (7)-crude LR-MS calculated for C20H28N6O4S2, found: 481 (M + H
+) 481. 
 
3.1.3.1.2.c.    Deprotection of compound (5)  
 
Compound 5 (0.82g; 0.97mmol) was deprotected using the method 
described in section 3.1.3.1.1.c. to yield a white precipitate (compound 8)   
N1,N1(disulfanediylbis(ethane-2,1-diyl))bis(N5-(2aminoethyl)disulfanyl)ethyl)glutaramide).  
 
(8) (0.49g; 60%), LR-MS for C22H44N6O4S6 [Mass: 648], found: 325 (M/2 + H)
 
(100%).  Other peaks of interest; 519 (M/2 + tBoc)+  (95%), 671 (M + Na+)  
(75%) 
 1H NMR (400 MHz, DMSO-d6)   δ (ppm): 1.70 (s, 4H, TFANH3
+CH2), 2.07 (m, 8H, 
CH2CH2CH2), 2.78(m, 8H, COCH2CH2), 2.95(m, 4H, NHCH2CH2), 3.08 (m, 4H, 
CH2CH2S), 3.32 (m, 8H, NHCH2CH2S), 8.09 (m, 10H, CONHCH2).  
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3.1.3.1.3.       Synthesis of Pro-drug Cystamine Citraconate   
di-tert-butyl ((9Z,21Z)-10,21-dimethyl-8,11,20,23-tetraoxo-3,4,15,16,27,28-hexathia-
7,12,19,24-tetraazatriaconta-9,21-diene-1,30-diyl)dicarbamate. (9) 
 
This compound was prepared using the same method for compounds (1) 
and (5). 
 
(9) (0.19g; 38%), LR-MS for C32H56N6O8S6 [Mass: 844], found: 845 (M + H)
 
(15%), 879 (M + Cl-) (75%).  Other peaks; for C9H20N2O2S2 [Mass: 252], found: 
253 (M + H) (35%) corresponding to Monoboc cystamine, and unidentifiable peak 
at 667 (100%). 
 
3.1.3.1.3.a.    Synthesis of N,N’-Citraconoylcystamine - Diamide (C) 
(2Z,2'Z)-4,4'-((disulfanediylbis(ethane-2,1-diyl))bis(azanediyl))bis(3-methyl-4-oxobut-2-
enoic acid).  (10) 
 
This compound was prepared from anhydrous citraconic acid (2.0g; 17.85 
mmol) using the method for diamides A and B. 
 
(10) (1.6g; 27%), mp 145˚C - 151˚C.  HR-MS (ESI): calculated for C14O19N2O6S2, 
375.0690, found: 375.0682 [M – H]-  (100%).  Figure B.1; Appendix 3 
1H NMR (400 MHz, DMSO-d6)   δ (ppm): 1.8 (s, 6H, CH3); 2.9 (t, 4H, CH2CH2S); 
3.1 (q, 4H, CH2CH2NH); 6.9 (s, 2H, CHCO); 7.1 (t, 2H, CH2NHCO); 9.1(s, 2H, 
CHCOOH).   
 
3.1.3.1.3.b.    Synthesis of the Imidazolide Derivative  
(Z)-N-(2-((2-((Z)-4-(1H-imidazol-1-yl)-2-methyl-4-oxobut-2-
enamido)ethyl)disulfanyl)ethyl)-4-(1H-imidazol-1-yl)-3-methyl-4-oxobut-2-enamide. (11) 
 
This compound was prepared from N,N’-Citraconoylcystamine (0.4 g; 1.07 
mmol) using the method described in section 3.1.3.1.1.b. but was not 
isolated. Over time, a colour change from pale pink to dark red was 
observed.  A red residue (9) was obtained following a solvent extraction 
with H2O and DCM (3 x 200mL). 
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(11)-crude LR-MS for C20H24N6O4S2 [Mass: 476], found: 477 (M + H
+) (85%), 
239 (M/2 + H+) (100%), 511 (M +Cl-) (100%).  
 
     3.1.3.1.4.         Synthesis of Pro-drug Cystamine Maleioate  
di-tert-butyl((9Z,21Z)-8,11,20,23-tetraoxo-3,4,15,16,27,28-hexathia-7,12,19,24-
tetraazatriaconta-9,21-diene-1,30-diyl)dicarbamate. (12) 
 
This compound was prepared using the same method for compounds 1, 5, 
and 9. 
(12) (0.37g, 41%) LR-MS for C30H52N6O8S6 [Mass: 816], found: 419.5 (M + 
Na+)/2 (100%); other peaks 815 (M – H+) (10%).  
 
3.1.3.1.4.a.      Synthesis of N,N’-Maleioylcystamine - Diamide (D) 
(2Z,2'Z)-4,4'-((disulfanediylbis(ethane-2,1-diyl))bis(azanediyl))bis(4-oxobut-2-enoic acid). 
(13) 
 
This compound was prepared from maleic anhydride (1.30g; 13.26 mmol) 
using the method for Diamides A, B, and C. 
 
(13) (0.27g, 59%). mp 160˚C - 175˚C.  HR-MS (ESI): calculated for 
C12H16N2O6S2, 347.0377 found: (M – H)
-  347,0371 (100%).  Figure B.2;  
Appendix 3 
1H NMR (400 MHz, DMSO-d6)   δ (ppm): 2.8 (t, 4H, CH2CH2S); 3.4 (q, 4H, 
NHCH2CH2); 6.2 (d, 2H, CHCHCO); 6.3 (d, 2H, CH-COOH); 7.9 (br, 2H, 
CONHCH2); 9.2 (t, 2H, CHCOOH).   
 
3.1.3.1.4.b.      Synthesis of the Imidazolide Derivative  
(2Z,2'Z)-N,N'-(disulfanediylbis(ethane-2,1-diyl))bis(4-(1H-imidazol-1-yl)-4-oxobut-2-
enamide). (14) 
 
This compound was prepared from N,N’-Maleinoylcystamine (0.5 g; 
1.43mmol) using the method described in section 3.1.3.1.1.b. and was 
not isolated.  A colour change from pale pink to dark red was also 
observed.  A red residue (12) was obtained by solvent extraction with H2O 
and DCM (3 x 200mL). 
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(14)-crude LR-MS for C18H20N6O4S2 [Mass: 448], found: 449 (M + H
+) (25%), 225 
(M + Na+)/2 (48%), 471 (M + Na+) (85%), 481 (M + CH3OH + H
+) (48%).  
 
3.2.        Synthesis of Novel Cystamine Pseudo-Peptides 
 
3.2.1.    Materials 
All chemicals were purchased from Sigma Aldrich, UK unless otherwise 
stated, and were used without further purification. 
   Dimethylformamide (DMF)…………………………………………Fisher Scientific (UK) 
   Dioxane…………………………………………………………………………Fisher Scientific (UK) 
   Piperidine………………………………………………………………………Fisher Scientific (UK) 
   H-Lys(Boc)-2-Cl-trt resin……………………………………………..Novabiochem    (UK) 
   1, 3-Diaminopropane trityl resin………………………………….Novabiochem    (UK) 
    
   H-Ala-2 Cl-trt resin……………………………………………………….Novabiochem    (UK) 
  
Fmoc-cystamine succinic and glutaric acids (15 and 16) were prepared by 
first dissolving cystamine dihydrochloride (2.25g; 10mmol) in H2O (30mL) 
and stirred in dioxane (100 mL).  The solution was then cooled in an ice 
bath to 0˚c for 10 minutes and succinic (1g; 10mmol) or glutaric 
anhydride (1.14g; 10mmol) was added.  The reaction mixture was stirred 
overnight at room temperature.  
After this time, DIPEA (3.3mL) and Fmoc-OSu (3.373g; 10mmol) in 10mL 
of DMF were successively added to the stirred solution in the ice bath at 0 
˚C and stirring continued for a further 2 hours.  The reaction product was 
collected by gravity filtration.  The filtrate was concentrated to a viscous 
liquid and H2O (200mL) was added producing a white precipitate, which 
was then collected by filtration, washed with H2O (2 x 200mL) and dried 
under vacuum.   
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Flash chromatography was performed using 5-10% Methanol in DCM.  The 
organic layer was dried with MgSO4, filtered and reduced to produce a 
white solid.181  
 
Fmoc N-protected cystamine succinic acid (15).  
Yield: 1.5g, 40%.  
LR-MS for C23H26N2O5S2 [Mass: 474], found: 475 (M + H
+) (100%), 497 (M + 
Na+) (85%), 473 (M – H+) (100%). 
1H NMR (400 MHz, DMSO-d6) δ (ppm): 2.3 (t, 2H, COCH2CH2), 2.4 (t, 2H, 
COCH2CH2), 2.74 (t, 4H, CH2CH2S), 3.3 (m, 4H, CH2CH2NH), 4.2 (t, 1H, CHCH2), 
4.3 (d, 2H, CHCH2O), 7.3 (m, 2H, Ar-H), 7.4 (t, 4H, Ar-H), 7.6 (d, 2H , Ar-H), 
7.87 (d, 2H, CH2NHCO), 8.0 (t, 1H, CH2COOH) Figure A.5;  Appendix 2 
 
Fmoc N-protected cystamine glutaric acid (16)  
Yield: 1.7g, 35%. 
LR-MS for C24H28N2O5S2 [Mass: 488], found: 489 (M + H 
+) (100%), 511 (M + 
Na+) (70%), 487 (M – H+) (100%). 
1H NMR (400 MHz, DMSO-d6) δ (ppm): 1.5 (m, 2H, CH2CH2CH2), 2.0 (t, 2H, 
CH2CH2CO), 2.3 (t, 2H, COCH2CH2), 2.58 (m, 4H, NHCH2CH2), 3.1(m, 4H, 
CH2CH2NHCO), 4.1 (m, 1H, CHCH2O), 4.15 (d, 2H, CHCH2), 7.1 (d, 2H, Ar-H), 7.2 
– 7.3 (m, 4H, Ar-H), 7.5 (d, 2H, Ar-H), 7.7 (d, 2H, CH2NHCO), 7.8 (t, 1H, 
CH2COOH). Figure A.6; Appendix 2 
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3.2.2.    Methods  
 
3.2.3.    Characterisation and Identification of Novel Pseudo-
Peptides 
 
All synthetic products were analysed for purity by Thin Layer 
Chromatography (TLC) and Mass Spectrometry (MS).  Solvent system 
used for thin layer chromatography (TLC), Dichloromethane: methanol 
(9:1). 
 
3.2.4. Solid Phase Peptide Synthesis (SPPS) using 1, 3- 
Diaminopropane trityl resin (DAP). 
 
3.2.4.1.   Synthesis of Fmoc-2[cystamine-succinic]–DAP 
(Fmoc2CSDAP) 
(9H-fluoren-9-yl)methyl (27-amino-8,11,20,23-tetraoxo-3,4,15,16-tetrathia-
7,12,19,24-tetraazaheptacosyl)carbamate.(17)  
 
3.2.4.1.1.   Resin swelling 
 
0.2g (0.16mmol) of diaminopropane resin was transferred into a vessel 
and 10mL of DCM was added.  The vessel was left in the fridge overnight.  
The next day DCM was flushed out and the resin was washed with DMF 
(3x10mL). 
 
3.2.4.1.2. Method A:   Peptide coupling 
 
HOBT (0.085g; 0.63mmol; 3.92 equivalents), TBTU (0.2g; 0.62mmol; 
3.94 equivalents) were dissolved in DMF (10mL) and added to the vessel 
containing the resin. 
DIPEA (110µL; 0.65mmol; 4 equivalents) was also added and the mixture 
left for 10 minutes at room temperature.  Compound 15 (0.3g; 0.66mmol; 
4 equivalents) was dissolved in DMF (5mL) and added to the mixture last.  
The mixture was mounted onto a Stuart Flash shaker (SF1) and shaken for 
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2 hours at a speed of 700 osc/min.  Additional coupling reactions were 
carried out using similar amounts of reagents and 15 and/or 16. 
 
3.2.4.1.3. Method B:   Kaiser Test 
 
After each cycle of coupling and deprotection, the reaction mixture was 
flushed out and washed with DMF (3x 10mL).  A few beads of dry resin 
were transferred into a micro-test tube and ninhydrin (6 drops), molten 
phenol solution (6 drops) and potassium cyanide solution (6 drops) were 
added.  The test tube was heated with a heat gun for 20 seconds.  
Colourless beads would indicate that coupling had taking place, whereas a 
purple colour would indicate a presence of a primary amine in the sample. 
 
3.2.4.1.4. Method C:   Amino Group Deprotection 
 
A mixture of DMF and piperidine (4:1, 20mL) was added to the washed 
resin and shaken for 2 hours.  
 
3.2.4.1.5. Method D:   Peptide Cleavage 
 
After the second coupling, the reaction mixture was flushed out and 
washed with DCM (10mL).  A solution of TFA in DCM (1% v/v; 10mL) was 
added and the reaction mixture was shaken for 2 hours, flushed out and 
washed with DCM (3 x 10mL).  The resulting filtrate was evaporated under 
vacuum to yield a viscous, hygroscopic residue which was treated with 
ethanol (3 x 15mL) and re-evaporated to dryness.   
Yield: 0.1g, 10%.  HR-MS (ESI): calculated for C34H49N6O6S4 765.2591, found: 
765.2583 [M + H]+ (100%).  Figure B.3; Appendix 3 
Other major peaks, (M + Cl-) 799 (85%), (M + FA – H+) 809 (100%), (M + TFA – 
H+) 877 (72%).   
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3.2.4.2.  Synthesis of Fmoc-3[cystamine-succinic]–DAP 
(Fmoc3CSDAP) 
(9H-fluoren-9-yl)methyl (39-amino-8,11,20,23,32,35-hexaoxo-3,4,15,16,27,28-
hexathia-7,12,19,24,31,36-hexaazanonatriacontyl) carbamate (18). 
 
This compound was prepared from diaminopropane resin (0.5g; 0.4mmol),  
HOBT (0.211g; 1.55mmol; 3.92 equivalents), TBTU (0.506g; 1.57mmol; 
3.94 equivalents), DIPEA (275µL; 1.59mmol; 4 equivalents) and 15 (0.76g; 
1.60mmol; 4 equivalents) using Method A.  The same amounts of reagents 
and 15 were used for all couplings. 
A Kaiser test and deprotection were performed using Method B and C 
respectively and the resulting oily product was obtained using Method D. 
       Yield: 0.55g, 11%. 
HR-MS (ESI): Calculated for C42H63N8O8S6  999.3088 [M + H]
+ , found: 999.3070 [M 
+ H] + (55%).  Figure B.4;  Appendix 3 
 
3.2.4.3.   Synthesis of Fmoc-[cystamine-glutaric]–DAP 
(FmocCGDAP)  
(9H-fluoren-9-yl)methyl (2-((2-(5-((3-aminopropyl)amino)-5-
oxopentanamido)ethyl)disulfanyl)ethyl)carbamate. (19) 
 
This compound was prepared from diaminopropane resin (0.2g; 0.16mmol),  
HOBT (0.085g; 0.63mmol; 3.92 equivalents), TBTU (0.2g; 0.62mmol; 3.94 
equivalents), DIPEA (110µL; 0.65mmol; 4 equivalents), and compound 16 
(0.313g; 0.64mmol) using Method A.  
A Kaiser test was performed using Method B. The peptide cleavage was 
carried out using Method D to yield a yellow viscous, oily product.  
Yield: 0.1g; 29%.   
HR-MS (ESI): calculated for C27H35N4O4S2 545.2251 [M + H]
+
 , found: 545.2255  
[M + H]+ (100%).  Figure B.5;  Appendix 3 
(173.17) non identifiable contaminant (100%), other peaks, (M + Na)+  567 (15%), 
657 (M + TFA – H)-  (100%), 589 (M + FA – H )-  (60%) 
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3.2.4.4.  Synthesis of Fmoc-2[cystamine-glutaric]–DAP 
(Fmoc2CGDAP)  
(9H-fluoren-9-yl)methyl (29-amino-8,12,21,25-tetraoxo-3,4,16,17-tetrathia-
7,13,20,26-tetraazanonacosyl)carbamate. (20) 
 
This compound was prepared from diaminopropane resin (0.5g; 0.4mmol),  
HOBT (0.211g; 1.55mmol; 3.92 equivalents), TBTU (0.506g; 1.57mmol; 
3.94 equivalents), DIPEA (275µL; 1.59mmol; 4 equivalents) and 16 (0.8g; 
1.60mmol; 4 equivalents) using Method A.  The same amounts of reagents 
and 16 were used for all couplings. A Kaiser test and deprotection were 
performed using Method B and C respectively, and the resulting oily product 
was obtained using Method D. 
Yield: 0.4g, 15%.  
HR-MS (ESI): calculated for C36H53N6O6S4 793.2904 [M + H
+]+, found: 793.2900 
(100%).  Figure B.6;  Appendix 3 
Other major peaks, (M + Na+) 815 (92%), (M/2 + H+) 397 (50%), (M +Cl-) 827 
(60%), (M + TFA – H+) 837 (80%).  
 
 
3.2.4.5. Attempted Synthesis of Fmoc-3[cystamine-glutaric]–DAP 
(Fmoc3CGDAP).(9H-fluoren-9-yl)methyl(42-amino-8,12,21,25,34,38-hexaoxo-
3,4,16,17,29,30-hexathia-7,13,20,26,33,39-hexaazadotetracontyl)carbamate. (21) 
 
This compound was prepared from diaminopropane resin (0.2g; 0.16mmol), 
HOBT (0.085g; 0.63mmol; 3.92 equivalents), TBTU (0.2g; 0.62mmol; 3.94 
equivalents), DIPEA (110µL; 0.65mmol; 4 equivalents), and compound 16 
(0.31g; 0.64mmol; 4 equivalents) using Method A.  
A Kaiser test and amino deprotection were performed using Method B and C 
respectively.  Peptide cleavage was carried out using Method D. 
Yield: 0.3g, 15%.  
LR-MS for C45H68N8O8S6 [Mass: 1014], no recognisable peak obtained. 
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3.2.4.6.   Synthesis of Fmoc-4[cystamine-glutaric]–DAP 
(Fmoc4CGDAP) 
(9H-fluoren-9-yl)methyl(55-amino-8,12,21,25,34,38,47,51-octaoxo-
3,4,16,17,29,30,42,43-octathia-7,13,20,26,33,39,46,52-
octaazapentapentacontyl)carbamate. (22) 
 
This compound was prepared from diaminopropane resin (0.3g; 0.24mmol), 
HOBT (0.127g; 0.94mmol; 3.92 equivalents), TBTU (0.303g; 0.2.93mmol; 
3.94 equivalents), DIPEA (165µL; 0.96mmol; 4 equivalents), and compound 
16 (0.47g; 0.0.96mmol; 4 equivalents) using Method A.  A Kaiser test and 
amino deprotection were performed using Method B and C respectively.  
Peptide cleavage was carried out using Method D. 
Yield: 0.25g, 5%  
LR-MS for C54H84N10O10S8 [Mass: 1288], found: 1289 (M + H
+) (25%), 1310 (M + 
Na+) (100%), 1287 (M – H+) (65%), 1323 (M + Cl-) (60%).  
 
 
3.2.4.7.   Synthesis of Fmoc-[cystamine-succinic-cystamine-
glutaric]–DAP (FmocCSGDAP)   
(9H-fluoren-9-yl)methyl (28-amino-8,11,20,24-tetraoxo-3,4,15,16-tetrathia-
7,12,19,25-tetraazaoctacosyl)carbamate (23) 
 
This compound was prepared from diaminopropane resin (0.2g; 0.16mmol), 
HOBT (0.085g; 0.63mmol; 3.92 equivalents), TBTU (0.2g; 0.62mmol; 3.94 
equivalents), DIPEA (110µL; 0.65mmol; 4 equivalents), compounds 15 
(0.30g; 0.66mmol; 4 equivalents) and 16 (0.31g; 0.64mmol; 4 
equivalents) using Method A.  A Kaiser test and amino deprotection were 
performed using Method B and C respectively.  Peptide cleavage was 
carried out using Method D to yield a colourless and viscous oily product. 
Yield: 0.076g, 8%.  
HR-MS (ESI): calculated for C35H51N6O6S4 779.2747 [M + H]
+ , found: 779.2738 [M 
+ H]+ (80%).  Figure B.7;  Appendix 3 
 Other major peaks, (M + Na+) 801 (70%), (M + K+)/2 + H+ 407 (65%), (M + Cl-) 
813 (70%), (M + FA – H+) 823 (55%). 
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3.2.5.  Solid Phase Peptide Synthesis using H-D-Alanine-2-
chlorotrityl resin.   
 
3.2.5.1.   Synthesis of Fmoc-2[cystamine-succinic]–Alanine (Fmoc-
2CS-Ala)(1-(9H-fluoren-9-yl)-3,12,15,24-tetraoxo-2-oxa-7,8,19,20-tetrathia-
4,11,16,23-tetraazaheptacosan-27-oyl)alanine. (24) 
 
This compound was prepared from alanine trityl resin (0.2g; 0.11mmol), 
HOBT (0.058g; 0.43mmol; 3.92 equivalents), TBTU (0.139g; 0.43mmol; 
3.94 equivalents), DIPEA (76µL; 0.44mmol; 4 equivalents), and compound 
15 (0.21g; 0.44mmol; 4 equivalents) using Method A. A Kaiser test and 
amino deprotection were performed using Method B and C respectively.  
Peptide cleavage was carried out using Method D producing a colourless oily 
product. 
Yield: 0.09g, 13%  
HR-MS (ESI): calculated for C34H46N5O8S4 780.2224 [M + H]
+ , found: 780.2226  
[M + H]+ (55%).  Figure B.8; Appendix 3 
 
3.2.5.2.   Synthesis of Fmoc-2[cystamine-glutaric]–Ala (Fmoc-2CG-
Ala) 
(1-(9H-fluoren-9-yl)-3,12,16,25-tetraoxo-2-oxa-7,8,20,21-tetrathia-4,11,17,24-
tetraazanonacosan-29-oyl)alanine. (25) 
 
This compound was prepared from alanine trityl resin (0.2g; 0.11mmol), 
HOBT (0.058g; 0.43mmol; 3.92 equivalents), TBTU (0.139g; 0.43mmol; 
3.94 equivalents), DIPEA (76µL; 0.44mmol; 4 equivalents), and compound 
16 (0.22g; 0.44mmol; 4 equivalents) using Method A. A Kaiser test and 
amino deprotection were performed using Method B and C respectively.  
Peptide cleavage was carried out using Method D to yield a colourless and 
viscous product. 
      Yield: 0.07g, 10%. 
      HR-MS (ESI): calculated for C36H50N5O8S4 808.2537 [M + H]
+, found: 808.2537 
      [M + H]+ (100%).   Figure B.9; Appendix 3 
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3.2.5.3.   Synthesis of Fmoc-2[cystamine-succinic-cystamine-
glutaric]–Ala (Fmoc-CS-CG-Ala)   
(1-(9H-fluoren-9-yl)-3,12,15,24-tetraoxo-2-oxa-7,8,19,20-tetrathia-4,11,16,23-
tetraazaoctacosan-28-oyl)alanine. (26) 
 
This compound was prepared from alanine trityl resin (0.2g; 0.11mmol), 
HOBT (0.058g; 0.43mmol; 3.92 equivalents), TBTU (0.139g; 0.43mmol; 
3.94 equivalents), DIPEA (76µL; 0.44mmol; 4 equivalents), and compounds 
15 (0.21g; 0.44mmol; 4 equivalents) and 16 (0.22g; 0.44mmol; 4 
equivalents) using Method A. A Kaiser test and amino deprotection were 
performed using Method B and C respectively.  Peptide cleavage was 
carried out using Method D to yield a colourless and viscous product. 
Yield: 0.08g, 11%.  
HR-MS (ESI): calculated for C35H48N5O8S4 794.2380 [M + H]
+, found: 794.2383 
(65%).  Figure B.10; Appendix 3 
 
3.2.6.   Solid Phase Peptide Synthesis using Lysine (Boc)2 –
chlorotrityl resin.  
3.2.6.1.   Synthesis of Fmoc-2[cystamine-succinic]–(Boc-Lys) 
(Fmoc-2CS-BocLys) 
N2-(1-(9H-fluoren-9-yl)-3,12,15,24-tetraoxo-2-oxa-7,8,19,20-tetrathia-
4,11,16,23-tetraazaheptacosan-27-oyl)-N6-(tert-butoxycarbonyl)lysine. (27) 
 
This compound was prepared from lysine 2-chlorotrityl trityl resin (0.2g; 
0.15mmol), HOBT (0.079g; 0.58mmol; 3.92 equivalents), TBTU (0.190g; 
0.59mmol; 3.94 equivalents), DIPEA (103µL; 0.60mmol; 4 equivalents), 
and compound 15 (0.28g; 0.60mmol; 4 equivalents) using Method A.  
A Kaiser test and amino deprotection were performed using Method B and C 
respectively.  Peptide cleavage was carried out using Method D to yield a 
colourless, oily product. 
Yield: 0.15g, 13%. 
HR-MS (ESI): calculated for C42H61N6O10S4 937.3327 [M+H]
+ , found: 937.3330.  
Calculated for 959.3146 [M+Na]+ , found: 959.3147 [M+Na]+.  Figure B.11; 
Appendix 3.  Other peaks, (M - tBoc) 837 (15%), (M - H+) 935 (45%). 
  
 
 
82 
 
3.2.6.2.    Synthesis of Fmoc-2[cystamine-glutaric]-(Boc-Lys) 
(Fmoc-2CG-BocLys)  
N2-(1-(9H-fluoren-9-yl)-3,12,16,25-tetraoxo-2-oxa-7,8,20,21-tetrathia-
4,11,17,24-tetraazanonacosan-29-oyl)-N6-(tert-butoxycarbonyl)lysine. (28) 
 
This compound was prepared from lysine 2-chlorotrityl trityl resin (0.3g; 
0.225mmol), HOBT (0.119g; 0.88mmol; 3.92 equivalents), TBTU (0.285g; 
0.89mmol; 3.94 equivalents), DIPEA (0.155µL; 0.90mmol; 4 equivalents), 
and compound 16 (0.44g; 0.90mmol; 4 equivalents) using Method A. A 
Kaiser test and amino deprotection were performed using Method B and C 
respectively.  Peptide cleavage was carried out using Method D to yield a 
colourless, oily product. 
Yield: 0.2g, 11% 
HR-MS (ESI): calculated for C44H65N6O10S4 965.3640 [M + H]
+, found: 965.3636 
(100%).  Figure B.12; Appendix 3 
Other major peaks,  (M + Na+) 987 (85%), (M – H+) 963 (100%). 
 
3.2.6.3.    Synthesis of Fmoc-[cystamine-succinic-cystamine-
glutaric]–(BocLys) (Fmoc-CS-CG-BocLys) 
N2-(1-(9H-fluoren-9-yl)-3,12,15,24-tetraoxo-2-oxa-7,8,19,20-tetrathia-
4,11,16,23-tetraazaoctacosan-28-oyl)-N6-(tert-butoxycarbonyl)lysine. (29) 
 
This compound was prepared from lysine 2-chlorotrityl trityl resin (0.3g; 
0.225mmol), HOBT (0.119g; 0.88mmol; 3.92 equivalents), TBTU (0.285g; 
0.89mmol; 3.94 equivalents), DIPEA (0.155µL; 0.90mmol; 4 equivalents), 
15 (0.43g; 0.90mmol; 4 equivalents) and 16 (0.44; 0.90mmol; 
4equivalents) using Method A. A Kaiser test and amino deprotection were 
performed using Method B and C respectively.  Peptide cleavage was 
carried out using Method D to produce a colourless, oily product. 
Yield: 0.18g, 10%  
HR-MS (ESI): calculated for C43H61N6O10S4 949.3337 [M - H]
-, found: 949.3283  
[M - H]- (100%).  Figure B.13; Appendix 3 
(M + Cl-) 985 (100%).   
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3.2.7.      Convergent Peptide Synthesis (CPS) 
 
3.2.7.1.    Synthesis of Fmoc-cystamine-succinic-DAP-succinic-
cystamine-Fmoc (Fmoc-CS-DAP-SC-Fmoc) .  
bis((9H-fluoren-9-yl)methyl) (8,11,17,20-tetraoxo-3,4,24,25-tetrathia-7,12,16,21-
tetraazaheptacosane-1,27-diyl)dicarbamate. (30) 
 
36 (0.053g; 0.1mmol), HOBT (0.014g; 0.10 mmol; 1.1 equivalents), and 
TBTU (0.033g; 0.10mmol; 1.1 equivalents) were dissolved in a small 
volume of DMF (5 mL) and after 10 minutes DIPEA (52µL; 0.31mmol; 3.2 
equivalents) was added.  The mixture was left for a further 10 minutes at 
room temperature and 15 (0.05g; 0.10mmol; 1.1 equivalents) was added 
last.  The reaction mixture was stirred for two days at room temperature 
and monitored by TLC.   
Liquid-liquid extraction was carried out with H2O and DCM (3 x 200 mL).  
The organic layer was dried with MgSO4, filtered and reduced to produce 
compound 30. 
Yield: 0.2g, 18 %. 
LR-MS for C49H58N6O8S4 [Mass: 988], found: 987 (M + H
+) (20%), 1025 (M + K+) 
(55%). 
 
3.2.7.2. Synthesis of Fmoc-cystamine-glutaric-DAP-glutaric-
cystamine-Fmoc (Fmoc-CG-DAP-GC-Fmoc).   
bis((9H-fluoren-9-yl)methyl) (8,12,18,22-tetraoxo-3,4,26,27-tetrathia-7,13,17,23-
tetraazanonacosane-1,29-diyl)dicarbamate. (31) 
 
To a solution of (19) (0.1g; 0.18mmol), HOBT (0.049; 0.36mmol; 2 
equivalents), TBTU (0.12g; 0.37mmol; 2 equivalents), and DIPEA (183µl; 
1.06mmol; 5.8 equivalents) in 5 mL of DMF was added 16 (0.18g; 
0.37mmol; 2 equivalents).  The mixture was stirred for 24 hours at room 
temperature and monitored by TLC.  The same amounts of coupling 
reagents were added to the stirred solution and stirring continued for a 
further 24 hours at room temperature.   
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Liquid-liquid extraction was carried out with H2O and DCM (3 x 200 mL).  
The organic layer was dried with MgSO4, filtered and reduced to produce a 
yellow solid (31). 
Yield: 0.13g, 23% 
LR-MS for C51H62N6O8S4 [Mass: 1014], found:  1015 (M + H
+) (15%), 1037 (M + 
Na+) (30%), 1049 (M + Cl-) (85%), 1059 (M + FA – H+) (100%). 
 
3.2.7.3.   Attempted synthesis of Fmoc-cystamine-glutaric-DAP-
succinic-cystamine-Fmoc (Fmoc-CG-DAP-SC-Fmoc).  
bis((9H-fluoren-9-yl)methyl) (8,11,17,21-tetraoxo-3,4,25,26-tetrathia-7,12,16,22-
tetraazaoctacosane-1,28-diyl)dicarbamate. (32) 
 
To a solution of (19) (0.086g; 0.16mmol) in 5 mL DMF was added HOBT 
(0.13mmol; 2 equivalents), TBTU (0.102g; 0.32mmol; 2 equivalents), and 
DIPEA (157µl; 0.9mmol; 5.8 equivalents). 15 (0.15g; 0.32mmol; 2 
equivalents) was then added to the mixture and the reaction mixture stirred 
for 2 days at room temperature and monitored by TLC.  Liquid-liquid 
extraction was carried out with H2O and DCM (3 x 200 mL).  The organic 
layer was dried with MgSO4, filtered and reduced to produce a yellow oily 
product 32. 
Yield: 0.05g, 11 % 
LR-MS for C50H60N6O8S4 [Mass: 1000.34], found 1000.34.  No identifiable peaks 
were obtained.   
 
3.2.7.4.   Attempted synthesis of Fmoc-cystamine-glutaric x 2-DAP-
glutaric-cystamine-Fmoc. (Fmoc-CG-DAP2GC-Fmoc-cystamine).  
bis((9H-fluoren-9-yl)methyl) (8,12,21,25,31,35-hexaoxo-3,4,16,17,39,40-
hexathia-7,13,20,26,30,36-hexaazadotetracontane-1,42-diyl)dicarbamate (33).   
 
This compound was prepared with 20 (0.1g; 0.126mmol), HOBT (0.019g; 
0.14 mmol; 1.1 equivalents), TBTU (0.044g; 0.13mmol; 1.1 equivalents), 
DIPEA (69µL; 0.4mmol; 3.2 equivalents), and 16 (0.11g; 0.22mmol; 1.1 
equivalents).  The reaction mixture was stirred for two days at room 
temperature and monitored by TLC.  The solution was partitioned between 
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DCM and water (3 x 200mL).  The organic layer was removed, dried with 
MgSO4, filtered and reduced to give a colourless oily product 33. 
Yield: 0.06g, 13% 
LR-MS for C60H78N8O10S6 [Mass: 1262.42].  No product peaks could be identified 
by m/s.  Other peaks of interest Fmoc-cystamine-glutaric acid [C24H28N2O5S2] (M 
+ Cl-) 523 (20%).   
 
3.2.7.5. Synthesis of Fmoc- x 2 [cystamine-succinic]– Lysine (Boc) 
– Fmoc. (Fmoc-2CS-Lys(Boc)-Fmoc-cystamine)  
bis((9H-fluoren-9-yl)methyl) (9-(4-((tert-butoxycarbonyl)amino)butyl)-8,11,14,23,26-
pentaoxo-3,4,18,19,30,31-hexathia-7,10,15,22,27-pentaazatritriacontane-1,33-
diyl)dicarbamate. (34)   
 
This compound was prepared using HOBT (0.028g; 0.27mmol; 2 
equivalents), TBTU (0.068g; 0.21mmol; 2 equivalents),  Fmoc-cystamine 
(0.079g; 0.21mmol; 2 equivalents), DIPEA (105µL; 0.61mmol; 5.8 
equivalents), and tBoc protected compound 27 (0.99g; 1.06mmol).  The 
reaction mixture was stirred overnight at room temperature.  Subsequent 
amounts of 27 and coupling reagents (double the equivalence) were 
added to the stirred solution and stirring continued for a further 24 hours, 
while the reaction was monitored by TLC.  The solution was partitioned 
between DCM and water (3 x 200mL).  The organic layer was removed, 
dried with MgSO4, filtered and reduced to give a yellow viscous, oily 
product 34.   
Yield: 0.09g, 10%.   
LR-MS for C61H80N8O11S6 [Mass: 1292], found: 1294 (10%), 1294 (M + 2H
+) 
(10%).   
 
3.2.7.6.   (Fmoc-2CS-Lys(Boc)-GC-Fmoc) Attempted synthesis of 
Fmoc- x 2 [cystamine-succinic] –Lys(Boc)-glutaric – cystamine-
Fmoc. 
29-(1-(9H-fluoren-9-yl)-3,12,16-trioxo-2-oxa-7,8-dithia-4,11,17-triazahenicosan-
21-yl)-1-(9H-fluoren-9-yl)-3,12,15,24,27-pentaoxo-2-oxa-7,8,19,20-tetrathia-
4,11,16,23,28-pentaazatriacontan-30-oic acid. (35)  
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Refer to 3.2.7.4.  This compound was prepared with HOBT (0.028g; 0.20 
mmol; 3.92 equivalents), TBTU (0.065g; 0.20mmol; 3.94 equivalents), 16 
(0.13g; 0.27mmol; 4 equivalents), DIPEA (36µL; 0.21mmol; 4 
equivalents), and tBoc deprotected compound 27 (0.044g; 53mmol) using 
the method described for 34.  A yellow viscous, oily product (35) was 
obtained. 
Yield: 0.075g, 19%. 
LR-MS for C61H78N8O12S6 [Mass: 1306.41]. No product peaks could be identified by 
m/s. Other peaks, (Fmoc-cystamine-glutaric) [C37H52N6O8S4, Mass: 488], found: 
489 (M + H+) (90%), 977 (2M + H+) (25%), 245 (M/2 + H+), 487 (M – H+) 
(100%). 
 
3.2.7.7.   Synthesis of Fmoc-cystamine-succinic-DAP (Fmoc(CS)-
DAP) 
9H-fluoren-9-yl) methyl (2-((2-(4-((3-aminopropyl)amino)-4-
oxobutanamido)ethyl)disulfanyl)ethyl)carbamate.  (36)  
 
This compound was prepared from diaminopropane resin (0.2g; 
0.16mmol), HOBT (0.085g; 0.63mmol; 3.92 equivalents), TBTU (0.2g; 
0.62mmol; 3.94 equivalents), DIPEA (110µL; 0.65mmol; 4 equivalents), 
and Fmoc N-protected cystamine-succinic (15) (0.3g; 0.66mmol; 4 
equivalents) using Method A.   A Kaiser test and amino deprotection were 
performed using Method B and C respectively.  Peptide cleavage was 
carried out using Method D. 
    Yield: 0.05g; 15% 
    LC-MS for C26H34N4O4S2 [Mass: 530], found: 531 (M + H
+) (100%), 553  
    (M + Na+) 553 (67%). 
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3.3.   Cell culture 
 
3.3.1.   Materials 
 
All cell culture reagents were purchased from Invitrogen (Paisley, UK), all 
plastics and glassware from FisherScientific UK Ltd. (Loughborough, UK) 
and all chemicals from Sigma-Aldrich (Poole, UK) unless otherwise stated 
and were used without further purification.  
 
3.3.2.   Human cystinotic fibroblasts (GM00008) 
 
Human cystinotic fibroblasts were purchased from Coriell Cell Repositories 
(NJ, USA) and were used to carry out all in vitro investigations. 
 
3.3.2.1.   Cell growth conditions 
 
Cell growth was carried out using under aseptic conditions in an Aura 
laminar flow air hood (Bioair Instruments, UK) using sterile plastics, 
glassware and solutions. 
Routine cells culture was carried out using Eagle’s minimum essential 
media (EMEM) supplemented with 15% foetal calf serum (FBS), 200 U mL-
1 Penicillin, 200 µgmL-1 Streptomycin and 2 mM Glutamine.   Growth 
conditions were sustained at 37˚C in a humidified atmosphere of 5% CO2 
/95% room air in a Hera cell 150 incubator (Heraeus, UK).  Cells multiplied 
in 75cm2 tissue culture flasks and cell confluence was monitored by 
visualisation using an inverted light Leica DMIL microscope 
(Microscopesystems Limited). 
The media was changed twice weekly and replaced with 12mL of fresh 
growth medium.   
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3.3.2.2.   Routine subculture 
 
Cells were collected by decanting the growth medium from the monolayer 
which was rinsed 3 times with sterile phosphate buffer saline (PBS). A 
solution of 0.05% Trypsin (5mL) was added to the monolayer and 
incubated for 5 minutes.  The cell monolayer was removed by gently 
rocking the flask, and an equal volume of medium containing FBS was 
added to neutralise the enzymatic action of the Trypsin.  The cell 
suspension was transferred into a sterile universal tube and the cell pellet 
was collected by centrifugation at 1200 rpm for 6 minutes.   After carefully 
removing the supernatant, the cell pellet was resuspended with 1mL of 
fresh medium.  The cell suspension was divided using a ratio of 1 to 3, and 
an equal volume of 333µL of cell suspension was introduced to sterile 
75cm2 flasks and supplemented with 12mL of fresh growth medium.  The 
flasks were placed in an incubator under aseptic conditions as previously 
described, and left undisturbed to allow cell adherence and growth.  Cell 
growth was checked regularly under a microscope.  Once reaching 80% 
confluence, the cells were prepared for experimental procedures, frozen in 
liquid nitrogen and stored as pellets at -80˚C. 
 
3.3.3.   Cell viability and proliferation 
 
3.3.3.1.   Trypan blue dye exclusion staining protocol 
 
Cystinotic fibroblasts were harvested from a 75cm2 flask using method 
3.3.2.2, and cell count was performed using method 3.3.3.1.   
A 1:1 dilution of the cell suspension (500µL) was prepared using 0.4%   
trypan blue solution and left to stand for 1-2 minutes to allow non viable 
cells to take up the colouring agent.   A small aliquot of the cell suspension 
was loaded into the counting chambers of a haemocytometer where the 
area under the cover slip was covered by means of capillary action.  Cell 
counting (viable and non viable) was performed visually using a 
microscope in the 25 squares. The total number of viable cells was 
calculated using the formula below. 
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      Number of cells/mL = Cell count per large square x Dilution factor x 10-4 cm3 
                                   (Volume of large square) 
 
 
3.3.3.2.   Alamar blue cell growth assay 
 
Following cell count described in 3.3.2.1, the cell suspension was diluted to 
25,000 cells mL-1 using growth media.  Cells were seeded in a 96 well 
sterile cell culture plates, at a density of 0.025 x 106 cells mL-1.  200µL of 
the diluted cell suspension was applied to the subsequent wells (i.e. 5000 
cells/well).   
The plates were transferred in an incubator under the same aseptic 
conditions described in section 3.3.2.1, and were allowed to adhere 
overnight.  The next day, cell adherence and initial growth were confirmed 
by microscopy.  Fresh growth medium supplemented with 10% (v/v) alamar 
blue (Serotec) was used and the plates were incubated in the presence of 
50µM either cysteamine, or novel compounds.  Vehicle control (0.5% 
DMSO) and untreated cell control were also used in the assay.  The assay 
was performed in triplicates and cell growth was measured at 0, 24, 48, and 
72 hours, by measuring the absorbance at 570nm using a Synergy/HT 
FL6000 microplate reader (Biotek).140 
 
3.3.4.   Quantitative Determination of Cysteine in Samples 
 
3.3.4.1   Thiol assay 
 
The assay was carried out using a method developed in house using freshly 
prepared buffers and solutions. 
Buffer A (5mM sodium acetate, 50mM NaCl, 0.5mM EDTA, pH 4.7). 
Buffer B (40mM sodium phosphate, 2mM EDTA, pH 7.6). 
Buffer C (5mM sodium acetate, pH 4.0). 
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Cells were harvested from a 75cm2 flask using method 3.3.2.2.   
A 10 mM stock solution (DMSO) for each of the compounds to be analysed 
and the controls (cysteamine and vehicle) was prepared in 0.5% DMSO 
(1mL). From the stock solution a 50 µM working solution (Growth Media) 
was then prepared for each sample. 
The cell pellets were removed from -80˚C freezer and immediately 
transferred to ice and resuspended in 200 µL of 1mM N-ethylamalimide 
prepared in phosphate buffer solution (pH 7.6).  Gentle pipetting was 
applied to break down the cell pellets.  Cell lysis was achieved by sonication 
in a sonic water bath for 10 seconds (step a) followed by 20 seconds of 
cooling on ice (step b).  Steps a. and b. were repeated a further 2 times.  
The solution was centrifuged (Biofuge primo R Heraeus centrifude) at 15000 
rpm for 10 minutes at 4˚C.  A portion of 100 µL of each cell lysate was 
removed and 10 µL of 4M NaBH4 in 0.1 M NaOH:DMSO was added.  To a 96 
well plate, 3 µL of buffer A was added, followed by a similar volume of the 
reduced sample lysates (prepared in cell lysis), followed by 100 µL of 
0.6mgmL-1 of papain-SSCH3 which was prepared by mixing equal volumes of 
1.2mgmL-1 papain-SSCH3 working solution with buffer B.  The plate was 
gently mixed and left to incubate for 1 hour at room temperature.  After 
this time, 100 µL of 4.9 mM L-BAPNA solution in buffer C was added to each 
well and the plate was gently mixed and left to incubate for a further 1 hour 
at room temperature.  The principle of the assay is summarised in diagram 
1.  The absorbance was measured at 410 nm using the plate reader.  The 
cysteine levels were recorded by comparison to known cysteine 
standards.140 
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Diagram 1 was obtained from www.lifetechnologies.com 
 
 
 3.3.4.2.   Bradford protein determination in samples 
 
This assay was performed according to the Bradford method on the same 
day as the cysteine quantity.140   A calibration using Bovine Serum Albumin 
(BSA prepared by dissolving 10mg of BSA in 10mL of dH2O) was also 
carried out.  The cell supernatant (40 µL) was diluted in 20 µL of dH2O and 
10 µL of the diluted cell supernatant (1:20) was added to a 96 wells plate.  
200 µL of Bradford reagent was added to each well containing the diluted 
samples and the plate was left to incubate for 5 minutes at room 
temperature.  The absorbance was measured at 595 nm using a plate 
reader.  The protein concentration was recorded by comparison to known 
BSA standards.140 
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       4.1. Multicomponent crystals 
      
       4.1.1. Results      
  
All of the crystals produced in this study used cysteamine as a starting 
materiel.  Notwithstanding this, the results showed that all new crystals 
formed were salts of cystamine except for cysteamine tartrate monohydrate.  
These findings were only revealed when X-ray diffraction analysis of the 
novel salts was carried out.  This is due to the tendency for cysteamine to 
oxidise to cystamine (the disulfide form of the compound) at room 
temperature in solution.   
       
      4.1.1.1.    Morphology of Novel Salts 
 
      4.1.1.1.a.    Cystamine Adipate  
    
 
 
  Figure 27.:  Image of crystals of Cystamine Adipate taken at 200x magnification using 
crossed polarizers 
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 4.1.1.1.b.     Cystamine 2,6 Dihydroxybenzoate  
 
 
Figure 28.:  Image of crystals of Cystamine 2,6 Dihydroxybenzoate taken at 200x 
magnification using crossed polarizers 
 
 
4.1.1.1.c.    Cystamine 3-Nitrobenzoate 
       
 
 
Figure 29.:  Image of crystals of Cystamine 3-Nitrobenzoate taken at 100x 
magnification using crossed polarizer 
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4.1.1.1.d.    Cystamine Glutarate 
 
 
Figure 30.:   Image of crystals of Cystamine Glutarate taken at 100x magnification 
using crossed polarizers 
 
 
 
4.1.1.1.e.    Cysteamine Tartrate Monohydrate 
 
 
 
Figure 31.:   Image of crystals of Cysteamine Tartrate Monohydrate taken at 100x 
magnification using crossed polarizers 
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4.1.1.1.f.      Cystamine Tartrate  
 
 
 
Figure 32.:  Image of crystals of Cystamine Tartrate taken at 50x magnification using 
crossed polarizers 
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4.1.1.2.   Melting Point 
 
 
Table 3.:  Melting Points for Starting Material, Co-Formers and Novel Salts 
Compound Literature 
Melting Point 
(˚C) 
Actual 
Melting 
Point (˚C) 
Novel Salts Melting Point of 
Novel Salts (˚C) 
Cysteamine 90-96      94-96    ------------    ------------ 
 
Cystamine      203-214 
 
    200-206    ------------    ------------ 
Adipic acid      151-154     151-154 Cystamine adipate     160 
2,6 Dihydroxybenzoic acid 
(2,6 DHBA) 
     165-168     165-168 Cystamine 2,6 
Dihydroxybenzoate 
219-220 
Glutaric acid       95-98      94-98 Cystamine Glutarate     143 
3-Nitrobenzoic acid (3-
NBA) 
     139-141       130 Cystamine 3-
Nitrobenzoate 
215-224 
L-Tartaric acid       168-170       169 Cysteamine Tartrate      75 
L-Tartaric acid       168-170       169 Cystamine Tartrate    114 
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4.1.1.3.   Differential Scanning Calorimetry (DSC) 
4.1.1.3.a.   Cystamine Adipate  
 
          
              Figure 33.:  Graph showing DSC results for Cystamine Adipate  
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4.1.1.3.b.   Cystamine 2,6 Dihydroxybenzoate  
 
 
 Figure 34.:  Graph showing DSC results for Cystamine 2,6 Dihydroxybenzoate   
 
 
4.1.1.3.c.  Cystamine Glutarate 
 
 
 Figure 35.:  Graph showing DSC results for Cystamine Glutarate 
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4.1.1.3.d.  Cystamine 3-Nitrobenzoate  
 
 
 Figure 36.:  Graph showing DSC results for Cystamine 3-Nitrobenzoate 
 
 
4.1.1.3.e.  Cysteamine Tartrate Monohydrate  
 
              Figure 37.:  Graph showing DSC resultss for Cysteamine Tartrate Monohydrate 
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4.1.1.3.f.  Cystamine Tartrate  
 
           Figure 38.:  Graph showing DSC results for Cystamine Tartrate 
 
 
4.1.1.4.   Principal IR absorbance bands 
 
Principal (IR) wavenumbers for all co-formers are shown in Table (4) 
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        Table 4.:   Principal IR wavenumbers for all co-formers.  
 
 
Compound Principal Bands 
wave number 
 (cm-1) 
Due to Group 
 
HOOC
COOH
 
 
Adipic Acid 
1681.03 
 
1189.82-1273.15 
 
C=O Stretching 
 
=C-O-C  
Stretching 
 
Carboxylic acid 
 
   
OH
O
OH
OH
 
 
2,6 Dihydroxybenzoic 
Acid 
     3075.81 
 
     1627-1471.24 
 
 
      1276.67 
C-H  Stretching 
 
Ring Vibrations 
 
 
O-H   Bending 
Aromatic 
 
Aromatic 
 
 
Aromatic 
 
 
HOOC COOH
 
 
Glutaric  Acid 
1681.03 
 
C=O  Stretching 
 
Carboxylic acid 
 
OH
O
NO2  
 
3- Nitrobenzoic  Acid 
 
1529.22-1448.94 
 
       
1290.83 
Ring vibrations 
 
 
C-O  Stretching 
Aromatic C=C 
stretching 
 
Carboxylic Acid 
 
       
   
    
HO
OH
O
O
HO
OH  
 
L- Tartaric Acid 
3403.27 
 
1736.52 
 
 
1252.38 
O-H  Stretching 
 
C=O  Stretching 
 
C-O  Bending 
 
Hydroxyl 
 
Carboxylic Acid 
 
 
Carboxylic Acid 
 
  
 
 
103 
 
 
       4.1.1.4.a.   IR spectra of Cystamine Adipate 
 
               Figure 39.:   IR spectra of sample Cystamine Adipate 
 
 
         4.1.1.4.b.   IR spectra of Cystamine 2,6 Dihydroxybenzoate  
                      
                    Figure 40.:  IR spectra of sample Cystamine - 2,6 Dihydroxybenzoate 
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         4.1.1.4.c.   IR spectra of Cystamine Glutarate  
 
   
 
               Figure 41.:   IR spectra of sample Cysteamine Glutarate  
 
 
         4.1.1.4.d.   IR spectra of Cystamine 3-Nitrobenzoate 
 
         Cystamine 3-nitrobenzoate 
 
     
       
 
 
 
 
 
 
 
 
                  Figure 42.:   IR spectra of sample Cysteamine 3-Nitrobenzoate 
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         4.1.1.4.e.   IR spectra of Cysteamine Tartrate 
 
          Cysteamine 
 
  
                Figure 43.:  IR spectra of sample Cysteamine Tartrate  
 
 
         4.1.1.4.f.   IR spectra of Cystamine Tartrate 
 
 
          Cystamine 
 
       
       Figure 44.:  IR spectra of sample Cystamine Tartrate 
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4.1.1.5.      X-Ray Crystallography Data of Novel Salts 
  
4.1.1.5.a.    X-Ray Crystallography Data for Cystamine Adipate [1:1] 
 
      Table 5.:  Crystal data and structure refinement for Cystamine  Adipate 
 
Formula                                      C4H14S2N2
2+. C6H8O4
2- 
Formula weight  298.42 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P ca21 
Unit cell dimensions a = 7.7274(3) Å  = 90°. 
 b = 16.7038(6) Å  = 90°. 
 c = 10.9188(3) Å  = 90°. 
Volume 1409.37(8) Å3 
Z 4 
Density (calculated) 1.406 Mg/m3 
Absorption coefficient 0.387 mm-1 
F(000) 640 
Crystal size 0.22 x 0.16 x 0.02 mm3 
Theta range for data collection 3.45 to 27.46°. 
Index ranges -10<=h<=7, -20<=k<=21, -14<=l<=10 
Reflections collected 8762 
Independent reflections 2874 [R(int) = 0.0424] 
Completeness to theta = 27.46° 99.5 %  
Max. & min. transmission 0.9923 and 0.9198 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2874 / 1 / 166 
Goodness-of-fit on F2 1.087 
Final R indices [I>2(I)] R1 = 0.0344, wR2 = 0.0815 
R indices (all data) R1 = 0.0368, wR2 = 0.0836 
Final weighting scheme calc w=1/2[(Fo2)+(0.0289P)2+1.1609P] 
where P=(Fo2+2Fc2)/3 
Absolute structure parameter 0.03(8) 
Largest diff. peak and hole 0.256 and -0.207 e.Å-3 
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Table 6.:  Hydrogen bonds for Cystamine Adipate [Å and °]. 
_______________________________________________________ 
        D-H...A           d(D-H) d(H...A)  d(D...A) <(DHA)                
_______________________________________________________ 
        N(1)-H(1A)...O(1)      2.09                     2.853(3) 141.2         
 N(1)-H(1B)...O(2)#1  0.91 1.89 2.767(3) 162.2 
 N(1)-H(1C)...O(1)#2  0.91 1.84 2.743(3) 173.3 
 N(1)-H(1C)...O(2)#2  0.91 2.65 3.234(3) 122.7 
 N(2)-H(2A)...O(4)#3  0.91 1.90 2.787(3) 165.2 
 N(2)-H(2B)...O(3)#4  0.91 1.79 2.693(3) 171.7 
 N(2)-H(2C)...O(4)#5  0.91 1.83 2.737(3) 175.8 
 N(2)-H(2C)...O(3)#5  0.91 2.62 3.191(3) 121.1 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+3/2,y,z+1/2    #2 x-1/2,-y+2,z    #3 -x+1,-y+1,z+1/2  
#4 x-1/2,-y+1,z    #5 -x+1/2,y,z+1/2  
 
 
 
Figure 45.:   Atomic arrangement in Cystamine Adipate  
 
Figure 45 shows that the product is a salt where one hydrogen ion from 
each carboxylic group C1 and C6 has been transferred to the N1and N2 
nitrogens of cystamine molecule.   
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4.1.1.5.b. X-ray crystallographic data for Cystamine - 2,6 
Dihydroxybenzoate [1:2] 
 
Table 7.:  Crystal data and structure refinement for Cystamine - 2,6-  
Dihydroxybenzoate 
 
Formula  C14H10O8
2- . C4H14N2S2
2+  
Formula weight  460.52 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 21.0281(10) Å = 90°. 
 b = 8.5309(5) Å  = 123.002(3)°. 
 c = 12.8186(7) Å   = 90°. 
Volume 1928.49(18) Å3 
Z 4 
Density (calculated) 1.586 Mg/m3 
Absorption coefficient 0.329 mm-1 
F(000) 968 
Crystal size 0.40 x 0.32 x 0.20 mm3 
Theta range for data collection 3.61 to 27.48°. 
Index ranges -27<=h<=25, -11<=k<=10, -14<=l<=16 
Reflections collected 10776 
Independent reflections 2211 [R(int) = 0.0672] 
Completeness to theta = 27.48° 99.6 %  
Max. and min. transmission 0.9372 and 0.8797 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2211 / 0 / 139 
Goodness-of-fit on F2 1.059 
Final R indices [I>2sigma(I)] R1 = 0.0408, wR2 = 0.0945 
R indices (all data) R1 = 0.0666, wR2 = 0.1072 
Final weighting scheme calc w=1/[2(Fo2)+(0.0508P)2+1.3325P] 
where P=(Fo2+2Fc2)/3 
Largest diff. peak and hole 0.315 and -0.366 e.Å-3 
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Table 8.:  Hydrogen bonds for Cystamine 2,6-Dihydroxybenzoate 
                [Å and°] 
_______________________________________________________ 
D-H...A             d(D-H)   d(H...A) d(D...A) <(DHA) 
_______________________________________________________ 
 N(1)-H(1A)...O(2)#1  0.91 2.17 3.040(2) 158.6 
 N(1)-H(1A)...O(1)#2  0.91 2.48 2.992(2) 116.0 
 N(1)-H(1B)...O(2)#3  0.91 2.03 2.913(2) 164.1 
 N(1)-H(1C)...O(4)#4  0.91 2.04 2.921(2) 161.8 
 O(1)-H(1D)...O(2)      0.84     1.82  2.570(2) 147.7 
 O(4)-H(4)...O(3)        0.84     1.75  2.500(2) 148.2 
_______________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 -x,y,-z+1/2    #2 x,y,z+1    #3 x,-y+1,z+1/2 
 
Figure 46.:  Atomic arrangement in Cystamine 2, 6 Dihydroxybenzoate 
 
Figure 46 shows that the product is a salt where one hydrogen ion from 
each carboxylic group has been transferred to the nitrogens N1 and N12 of 
cystamine molecule.   
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4.1.1.5.c.    X-Ray Crystallography Data for Cystamine Glutarate [1:1] 
 
Table 9.:  Crystal data and structure refinement for Cystamine Glutarate.   
 
Formula  C2H10NS
2+. C5H10O2
2- 
Formula weight  284.39 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 8.4519(2) Å = 90°. 
 b = 17.3693(6) Å  = 92.498(2)°. 
 c = 8.8427(2) Å   = 90°. 
Volume 1296.91(6) Å3 
Z 4 
Density (calculated) 1.457 Mg/m3 
Absorption coefficient 0.416 mm-1 
F(000) 608 
Crystal size 0.59 x 0.40 x 0.12 mm3 
Theta range for data collection 3.29 to 27.45°. 
Index ranges -10<=h<=10, -22<=k<=21, -11<=l<=11 
Reflections collected 15899 
Independent reflections 2954 [R(int) = 0.0351] 
Completeness to theta = 27.45° 99.8 %  
Max. and min. transmission 0.9518 and 0.7913 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2954 / 0 / 154 
Goodness-of-fit on F2 1.061 
Final R indices [I>2sigma(I)] R1 = 0.0299, wR2 = 0.0739 
R indices (all data) R1 = 0.0345, wR2 = 0.0771 
Final weighting scheme calc w=1/[2(Fo2)+(0.0360P)2+0.7531P] 
where P=(Fo2+2Fc2)/3 
Largest diff. peak and hole 0.383 and -0.310 e.Å- 
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Table 10.:  Hydrogen bonds for Cystamine Glutarate [Å and °]. 
_______________________________________________________ 
D-H...A               d(D-H)   d(H...A) d(D...A) <(DHA) 
_______________________________________________________ 
 N(1)-H(1A)...O(1)#1  0.91 1.88 2.7512(15) 158.8 
 N(1)-H(1B)...O(2       0.91 1.92 2.7743(15) 154.7 
 N(1)-H(1C)...O(3)#3  0.91 1.96 2.8419(15) 164.2 
 N(2)-H(2A)...O(2)      0.91      1.82       2.6799(15)      155.9 
 N(2)-H(2B)...O(4)#4  0.91 1.91 2.8212(14) 176.4 
 N(2)-H(2C)...O(4)#5  0.91 1.98 2.8638(15) 164.6 
_______________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,-y,-z+1    #2 x,y,z+1    #3 x+1,-y+1/2,z+1/2  
#4 x+1,-y+1/2,z-1/2    #5 x+1,y,z  
 
 
Figure 47.:  Atomic arrangement in Cystamine Glutarate 
 
Cystamine glutarate (Figure 47) is a salt formed by transfer of both 
hydrogen ions from the two carboxylic acid groups C5 and C9 in the tartaric 
acid molecule to the two amino groups N1 and N2 in cystamine. 
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4.1.1.5.d.    X-ray crystallography data for Cystamine 3-Nitrobenzoate 
[2:4] 
 
Table 11.:  Crystal data and structure refinement for cystamine 3-   
Nitrobenzoate  
 
Formula  C4H14N4S2
2+.C14H15O8
2- 
Formula weight  3892.13 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 13.6477(3) Å = 90°. 
 b = 24.3527(5) Å  = 116.9700(10)°. 
 c = 14.7148(2) Å  = 90°. 
Volume 4358.70(14) Å3 
Z 4 
Density (calculated) 1.483 Mg/m3 
Absorption coefficient 0.298 mm-1 
F(000) 2032 
Crystal size 0.38 x 0.25 x 0.21 mm3 
Theta range for data collection 2.95 to 27.50°. 
Index ranges -16<=h<=17, -31<=k<=31, -19<=l<=19 
Reflections collected 43615 
Independent reflections 9973 [R(int) = 0.0494] 
Completeness to theta = 27.50° 99.7 %  
Max. and min. transmission 0.9401 and 0.8952 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9973 / 0 / 581 
Goodness-of-fit on F2 1.036 
Final R indices [I>2sigma(I)] R1 = 0.0474, wR2 = 0.1176 
R indices (all data) R1 = 0.0770, wR2 = 0.1321 
Final weighting scheme calc w=1/[2(Fo2)+(0.0587P)2+2.0386P] 
where P=(Fo2+2Fc2)/3 
Largest diff. peak and hole 0.633 and -0.422 e.Å-3 
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Table 12.:  Hydrogen bonds for Cystamine 3-Nitrobenzoate [Å and °]. 
_______________________________________________________ 
D-H...A              d(D-H)    d(H...A) d(D...A) <(DHA) 
_______________________________________________________ 
 N(1)-H(1A)...O(6)#1    0.91 1.85 2.742(2) 165.7 
 N(1)-H(1B)...O(14)#2  0.91 2.01 2.825(2) 148.8 
 N(1)-H(1B)...O(4)#2    0.91 2.56 3.154(2) 123.7 
 N(1)-H(1C)...O(10)#3  0.91 1.86 2.767(2) 175.0 
 N(2)-H(2A)...O(13)#4  0.91 1.79 2.692(2) 170.1 
 N(2)-H(2B)...O(2)#5    0.91 1.94 2.829(2) 164.7 
 N(2)-H(2C)...O(2)#6    0.91 1.95 2.788(2) 151.9 
 N(3)-H(3C)...O(1)#5    0.91 1.76 2.655(2) 167.0 
 N(3)-H(3D)...O(6)#5    0.91 1.95 2.833(2) 163.3 
 N(3)-H(3E)...O(14)       0.91 1.96 2.813(2) 154.7 
 N(4)-H(4C)...O(9)#4    0.91 1.87 2.758(2) 166.3 
 N(4)-H(4D)...O(9)#3    0.91 2.03 2.819(2) 143.8 
 N(4)-H(4D)...O(16)#6  0.91 2.60 3.239(2) 127.7 
 N(4)-H(4E)...O(5)#7    0.91 1.83 2.728(2) 169.5 
_______________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,y-1/2,-z+3/2    #2 x,y,z+1    #3 x+1,y,z+1  
#4 -x+1,-y,-z+1    #5 -x+1,y-1/2,-z+1/2    #6 x,-y+1/2,z+1/2  
#7 x+1,-y+1/2,z+1/2  
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Figure 48.:   Atomic arrangement in Cystamine 3-Nitrobenzoate 
 
This product (Figure 48) is a salt formed by transfer of both hydrogen ions 
from eight carboxylic acid groups in four molecules of tartaric acid to the 
four amino groups N1, N2, N3, and N4 in two molecules of cystamine. 
 
4.1.1.5.e.    The crystal data for samples cysteamine tartrate monohydrate [1], 
cystamine tartrate [2], and cystamine bitartrate dehydrate [3]  
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Table 13.   X-ray crystallographic data for 1, 2, and 3. 
 
 
Compound 1 2 3 
Formula C2H8NS.C4H5O6.H2O C4H14N2S2
2+. 
C4H4O6
2- 
C4H14N2S2
2+. 
2C4H5O6
- 
.2H2O 
Formula weight 245.25 302.36 488.48 
Crystal size (mm) 0.84 x 0.12 x 0.10 0.36 x 0.14 
x 0.03 
0.22 x 0.02 
x 0.02 
Crystal shape Rod cut blade Needle 
Crystal colour Colourless Colourless Colourless 
Space group P 212121 P 212121 P 212121 
Unit cell dimensions:    
a [Å] 7.0630(2) 5.7281 (3) 7.3425 (5) 
b [Å] 10.3833(5) 9.3699 (5) 10.5227 (8) 
c [Å] 14.8591(7) 24.6770 
(14) 
26.983 (2) 
 [] 90 90 90 
 [] 90 90 90 
  [] 90 90 90 
V [Å3] 1089.73(8) 1324.46 
(12) 
2084.8 (3) 
Z 4 4 4 
D calc [g cm
-3] 1.495 1.516 1.556 
Absorption coefficient        
µ [mm-1] 
0.31 0.423 0.329 
F(000) 520 640 1032 
Scan mode  -  scans  -  scans  -  scans 
 range [] 2.91 – 27.48 2.91 – 
27.48 
2.91 – 
27.48 
Index ranges -9h8 -7h7 -8h8 
 -13k13 -12k12 -12k12 
 -17l19 -32l29 -32l30 
Reflections collected 9253 9158 12189 
Rint 0.0509 0.0830 0.0841 
Data/restraints/parameters 2485/ 0/143 3020/0/165 3527/6/291 
Goodness of fit on F2  1.064 1.046 1.093 
Absolute structure parm. -0.04(9) 0.20(13) -0.1(2) 
R [I ≥ 2(I)] / R (all data) 0.0387 / 0.0873 0.0601 / 
0.1268 
0.0783 / 
0.1309 
wR [I ≥ 2(I)] / wR [all 
data] 
0.0510 / 0.0932 0.0879 / 
0.1393 
0.01259 / 
0.1517 
Max/Min residual electron 
density [eÅ-3] 
0.268 / -0.254 0.553 / -
0.430 
0.421 / -
0.392 
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Molecular plots for (1), (2) and (3) are shown in Figures (49), (50) and (51) 
respectively. 
    
Figure 49.:  Atomic arrangement in Cysteamine Tartrate Monohydrate (1). 
 
 
For (1) the salt formation results from the transfer of a proton from one of 
the two carboxylic acid groups in the tartaric acid molecule to the amino 
group N1 in cysteamine. 
 
        Figure 50.:  Atomic arrangement in Cystamine Tartrate (2) 
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Product (2) is an anhydrous salt formed by transfer of both hydrogen ions from 
the two carboxylic acid groups in tartaric acid to the two amino groups N1 and 
N2 in cystamine 
 
 
 
            Figure 51.:  Atomic arrangement in Cystamine Bitartrate Dihydrate (3) 
 
 
As in (2) both amino groups N1 and N2 have acquired an additional 
hydrogen ion. This proton transfer occurred from separate tartaric acid 
molecules leaving a single charge on each bitartrate anion. 
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Table 14.:   Hydrogen bonding for (1) 
 
D-H...A                   d(D-H)    d(H...A)    d(D...A) <(DHA) 
        O(1)-H(1).....O(6)#1     0.84       1.66        2.4885(18)  169.3 
O(3)-H(3).....O(7)#2     0.84       2.13     2.819(2)  139.0 
O(4)-H(4).....O(7)         0.84       1.90     2.742(2)  177.2 
N(1)-H(1A)...O(3)#3     0.91        2.00     2.813(2) 148.2 
N(1)-H(1B)....O(2)#4    0.91    1.92     2.814(2) 165.9 
N(1)-H(1C)....O(5)#1    0.91    1.89     2.772(2) 161.8 
N(1)-H(1C)...O(4)#1     0.91     2.30     2.850(2) 118.4 
O(7)-H(7A)...O(5)#1     0.87     1.89         2.7455(19) 168.1 
O(7)-H(7B)...O(6)#5     0.77      2.14         2.8910(19) 166.4 
Symmetry transformations used to generate equivalent atoms:  
#1 x+1,y,z    #2 –x+1,y-1/2,-z+1/2    #3 –x+1,y+1/2,-z+1/2  
#4 –x+2,y+1/2,-z+1/2    #5 x+1/2,-y+1/2,-z+1  
 
 
Table 15.:   Hydrogen bonding for (2) 
 
 D-H...A                d(D-H)    d(H...A)    d(D...A)   <(DHA) 
 N(1)-H(1A)...O(1)#1   0.91 1.88 2.786(4) 174.9 
 N(1)-H(1B)...O(2)#2   0.91 1.82 2.705(4) 162.2 
 N(1)-H(1C)...O(1)#3   0.91 1.99 2.892(4) 170.2 
 N(2)-H(2A)...O(3)#4   0.91 1.99 2.871(4) 161.3 
 N(2)-H(2B)...O(6)#5   0.91 1.77 2.684(4) 177.1 
 N(2)-H(2C)...O(5)#6   0.91 1.87 2.727(4) 155.3 
 O(3)-H(3)...O(1)         0.84       2.09 2.588(4) 117.4 
 O(3)-H(3)...S(1)#7     0.84       2.92 3.703(3) 156.4 
 O(4)-H(4)...O(5)         0.84      2.13  2.613(4)  116.1 
 O(4)-H(4)...O(2)#8     0.84      2.20  2.889(4)   139.4 
Symmetry transformations used to generate equivalent atoms:  
#1 x-1,y+1,z    #2 x-3/2,-y+1/2,-z    #3 x-1/2,-y+1/2,-z  
#4 x,y+1,z    #5 –x+2,y+1/2,-z+1/2    #6 –x+1,y+1/2,-z+1/2  
#7 x,y-1,z    #8 x-1,y,z  
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Table 16.:    Hydrogen bonding for (3) 
 
 D-H...A                      d(D-H)     d(H...A)      d(D...A)      <(DHA) 
 N(1)-H(1A)...O(11)#1   0.91         1.90           2.789(8)        164.4 
 N(1)-H(1B)...O(2)         0.91         2.32           2.861(8)        118.1 
 N(1)-H(1B)...O(5)#1     0.91         2.34           2.983(8)        127.1 
 N(1)-H(1C)...O(10)       0.91         1.97           2.860(7)        164.2 
 N(2)-H(2A)...O(5)#2     0.91         1.87           2.742(8)        159.8 
 N(2)-H(2B)...O(7)#3     0.91         2.16           2.948(8)        144.7 
 N(2)-H(2B)...O(9)#3     0.91         2.27           2.987(8)        135.7 
 N(2)-H(2C)...O(4)#3     0.91         1.87           2.766(7)        169.0 
 O(1)-H(1).....O(6)#1     0.84         1.73          2.555(7)        167.4 
 O(3)-H(3).....O(14)       0.84         2.39           2.818(8)        112.6 
 O(4)-H(4).....O(5)         0.84         2.07           2.577(7)        118.3 
 O(4)-H(4).....O(13)#4   0.84         2.23           2.942(8)        142.6 
 O(9)-H(9).....O(13)#5   0.84         1.85           2.683(7)        170.6 
 O(10)-H(10)..O(11)       0.84         2.05           2.572(7)        119.3 
 O(12)-H(12)..O(8)#4     0.84        1.66           2.476(7)        164.9 
 O(13)-H(13A).O(7)        0.85(2)    1.99(4)      2.743(7)        148(7) 
 O(13)-H(13B)..O(9)#1   0.85(2)    2.00(2)      2.833(7)       170(7) 
 O(14)-H(14A)...O(10)    0.86(2)    2.51(6)      3.171(9)        135(7) 
 O(14)-H(14B)...O(6)#6  0.87(2)   1.97(4)       2.787(8)       156(9) 
Symmetry transformations used to generate equivalent atoms:  
#1 x+1,y,z    #2 x+1,y-1,z    #3 x,y-1,z    #4 x-1,y,z  
#5 x-1/2,-y+3/2,-z    #6 –x,y-1/2,-z+1/2  
 
 
4.1.1.6.   Other acids used as co-formers for co-crystal synthesis 
 
Acids such as benzoic acid; 2,5 dihydroxybenzoic acid, oxalic acid; 
paracetamol; phenol; saccharin; sulfamethoxazole; and salicylic acid were 
used as co-formers to synthesise co-crystals of cysteamine.  However, 
these co-formers did not generate any novel products. The results were 
confirmed by mp and IR spectra which indicated the presence of starting 
materials, i.e. the corresponding acids. 
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4.1.2.     Discussion 
 
       4.1.2.1.   Cystamine Adipate  
The melting point for this compound was higher than both the starting 
material and its co-former as shown in Table (3). This was confirmed by 
DSC (Figure 33).  The IR spectrum (Figure 39) of cystamine adipate 
displayed different absorbances when compared to both starting materials.   
The peak at 2843 cm-1 present on the cysteamine spectrum corresponding 
to an N-H stretching band had disappeared on the cystamaine adipate 
spectra.  The peak corresponding to the O-H stretching band at 2945.50 
cm-1 present on the adipic acid spectrum had also disappeared and a new 
peak at 2359.81 cm-1 was present.  In addition, the N-H bending band at 
1584.40 cm-1 in cysteamine had slightly shifted to 1550.95 cm-1 due to 
hydrogen bonding within the new compound.  Moreover, the results in Table 
(6) show that these crystals are held together by extensive intermolecular 
hydrogen bonding with d(D-H)= 0.91Å, and an angle (DHA) of almost 180˚.  
These two parameters are indicative of strong intermolecular hydrogen 
bonding between the donor and the acceptor site.   
Additionally, Figure (45) typically shows salt formation by transfer of both 
hydrogen atoms from the two carboxylic acid groups of adipic acid to the 
two amine nitrogen atoms of cystamine.  This is confirmed by bond 
character in the carboxylate groups shown by C(1)-O(1) = 1.268(3)Å, C(1)-
O(2) = 1.261(3)Å, C(6)-O(3) = 1.258(8)Å and C(6)-O(4) = 1.268(3)Å. 
 
       4.1.2.2.   Cystamine 2,6 Dihydroxybenzoate  
By displaying a different melting point to both starting materials as shown 
in Table (3), a change in the physical properties indicates the potential for a 
newly formed compound; this was also confirmed by DSC (Figure 34).  IR 
spectral interpretation (Figure 40) indicated a shift of the O-H stretching 
band from 2973cm-1 in 2, 6 dihydroxybenzoic acid to 2916cm-1 in the newly 
formed compound resulting from hydrogen bonding between the co-former 
and the new compound.  This was confirmed by transfer of the hydrogen 
atom from the carboxylic acid groups of 2, 6 dihydroxybenzoic acid to the 
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two amine nitrogen atoms of cystamine (Figure 46).  Bond character in the 
carboxylate groups was shown by C(7)-O(2) = 1.279(2)Å, C(7)-O(3) = 
1.263(2)Å. Extensive hydrogen bonding is also present. (Table 8) 
 
        4.1.2.3.   Cystamine Glutarate   
The melting point for this compound was found to be much higher than both 
the starting material and its co-former as shown in Table (3). This was 
confirmed by DSC (Figure 35).  IR spectra (Figure 41) of cystamine 
glutarate displayed different peaks when compared to those of both starting 
materials.   The peak at 2843 cm-1 present on the cysteamine spectrum 
corresponding to N-H stretching band had disappeared on the compound 
spectrum.  The peak corresponding to the O-H stretching band at 2952 cm-1 
present in the glutaric acid spectrum had also disappeared and a new peak 
at 2733 cm-1 was formed.  In addition, the N-H bending band at 1584 cm-1 
in cysteamine had slightly shifted to 1541 cm-1 due to hydrogen bonding 
with the new compound. The above results confirm that a new crystal 
compound had been formed. Transfer of the hydrogen atom from the 
carboxylic acid group of glutaric acid to the two amine nitrogen atoms of 
cystamine (Figure 47) also confirms the formation of a novel salt, where 
bond character in the carboxylate groups is shown by C(5)-O(1) = 
1.2447(17)Å, C(5)-O(2) = 1.2669(16)Å, C(9)-O(3) = 1.2512(16)Å, C(5)-
O(2) = 1.2729(16)Å.  Table (10) confirms that these crystals are held 
together by very strong hydrogen bonding.  
 
4.1.2.4.   Cystamine 3- nitrobenzoate  
 
The melting point for this compound was found to be considerably higher 
than both the starting material and its co-former as shown in Table (3). This 
was confirmed by DSC (Figure 36).  IR spectra (Figure 42) of cystamine 3- 
nitrobenzoate displayed different absorbances when compared to those of 
both starting materials.   Hydrogen bonding with cysteamine has caused the 
peak at 2843.22 cm-1 present on the cysteamine spectrum corresponding to 
N-H stretching band to shift to 2929.06 cm-1 on the compound spectrum.  A 
  
 
 
122 
 
shift of the C-O stretching band in 3-Nitrobenzoic acid from 1290.17 cm-1 to 
1229.99 cm-1 was also noted. 
In this compound (Figure 48) both nitrogen atoms in cystamine molecule 
have also acquired an additional hydrogen atom resulting in ionisation.  
Evidence of this proton transfer is based on the bond character in the 
carboxylate group and is shown by C(15)-O(1) = 1.253(2)Å, C(15)-O(2) = 
1.1263(2)Å, C(22)-O(5) = 1.255(2)Å, C(22)-O(6) = 1.1266(2)Å, C(29)-
O(9) = 1.265(2)Å, C(29)-O(12) = 1.253(2)Å, C(36)-O(13) = 1.249(2)Å, 
C(36)-O(14) = 1.263(2)Å 
As with all novel salts mentioned above, this crystal material also displayed 
strong hydrogen bonding. (Table 12) 
 
Compounds (1), (2) and (3) described in the sections below were formed 
from the same reaction using cysteamine and tartaric acid as the starting 
materials. 
 
4.1.2.5.   Cysteamine Tartrate Monohydrate (1) 
 
The melting point compound (1) was found to be between both the starting 
material and its co-former as shown in Table (3). This was confirmed by 
DSC (Figure 37).   
IR spectra (Figure 43) of compound (1) displayed different absorbances 
when compared to those of both starting materials.   Hydrogen bonding 
with cysteamine has caused the peak at 2843.22 cm-1 present on the 
cysteamine spectrum corresponding to N-H stretching band to shift to 
2909.02 cm-1 on spectrum.  A shift of the C-O stretching band in tartaric 
acid from 1172.46 cm-1 to 1249.30 cm-1 was also noted. 
The above results confirm that a new crystal compound had been formed. 
For compound (1) (Figure 49) the product is clearly seen to possess a 
hydrogen atom attached to the sulfur with a sulfur-hydrogen bond length of 
1.31(3) Å. Only one of the hydrogen atoms from the two carboxylic acid 
groups has transferred to the nitrogen. The single bond character of C3-O1 
= 1.301(2) Å compares with the double bond for C3-O2 = 1.224(2) Å and 
with the bonds in the carboxylate group, i.e., C6-O5 = 1.240(2) Å and C6-
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O6 = 1.280(2) Å. The crystals are held together by extensive hydrogen 
bonding (Table 14). A water molecule is present in the crystal and this is 
hydrogen bonded to the carboxylate group and to the hydroxyl groups at 
O3 and O4. 
 
        4.1.2.6.      Cystamine Tartrate Mixture 
 
 
4.1.2.6.a.   Cystamine Tartrate (2) 
    
The resulting melting point (Table 3) for the crystal compound (2) was 
lower than the starting material and its co-former.  These results were 
confirmed by DSC (Figure 38).  In addition, IR spectra (Figure 44) showed a 
shift of the N-H stretching band of cystamine from 2917.27 cm-1 to 2890.58 
cm-1 due to hydrogen bonding with the new compound.  Hydrogen bonding 
with cystamine has also caused the peak at 1593.55 cm-1 present on the 
cystamine spectrum corresponding to N-H stretching band to shift to 
1606.46 cm-1 on the compound spectra.  A shift of the C-O stretching band 
from 1184.01 cm-1 to 1127.32 cm-1 was also noted. 
Molecule (2) (Figure 50) is a typical anhydrous salt formed by transfer of 
both hydrogen atoms from the two carboxylic acid groups to the two amine 
nitrogen atoms (i.e. full ionisation). Bond character in the carboxylate 
groups is shown by C(5)-O(1) = 1.257(5)Å, C(5)-O(2) = 1.244(5)Å, C(8)-
O(5) = 1.258(5)Å and C(8)-O(6) = 1.251(5)Å. The sulfur-sulfur bond length 
is 2.038(2)Å. As in compound (1) extensive hydrogen bonding is present 
(Table 15).  
 
 
4.1.2.6.b.   Cystamine Bitartrate  Dihydrate (3) 
 
The quality of the data set related to the crystal for compound (3) (Figure 
51) was not as good as those obtained for compounds (1) and (2) and 
discussion of the fine details of the molecular structure needs to be 
approached with caution.  As in 2 both nitrogen atoms have acquired an 
additional hydrogen atom resulting in ionisation. Each of these two protons 
appears to have transferred from separate tartaric acid molecules leaving a 
single charge on each anion.  Evidence for this is again based on bond 
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lengths such that for the carboxylic acid group C(5)-O(1) = 1.292(9)Å, 
C(5)-O(2) = 1.191(9)Å and in the same anion the carboxylate group has 
C(8)-O(5) = 1.261(8)Å and C(8)-O(6) = 1.231(8)Å.  
In the second anion the bond character is less obvious but it appears the 
carboxylic acid group has C(12)-O(11) = 1.220(9)Å and C(12)-O(12) = 
1.274(9)Å and in the carboxylate group these bonds are C(9)-O(7) = 
1.229(9)Å and C(9)-O(8) = 1.278(8)Å. As in compound (1) and (2) 
extensive hydrogen bonding is present (Table 16).  
Other models were tried, i.e. proton transfer from a single tartaric acid 
molecule and the possibility of H3O
+ formation, however, the refinement of 
these models were less satisfactory than the one presented. The sulfur – 
sulfur bond length is 2.038(3)Å. These values are in good agreement with 
the literature values of 2.00Å.161 
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4.2.   Synthesis of novel cystamine Pro-drugs derivatives 
 
The objectives of the work described in this thesis were the design, 
synthesis and in vitro evaluation of novel pro-drugs for the treatment of 
Nephropathic Cystinosis.  The current treatment (Cystagon®), although 
effective is known to cause both gastric irritation when taken orally and 
possesses a foul taste and smell.  These side effects associated with its 
administration are caused by the presence of both an amine and a thiol 
functional group in the molecule.140,141,143 
In order to minimise the side effects and to improve patient compliance, 
previous work undertaken in our laboratories concentrated on the design 
and production of pro-drugs designed to decompose to release cysteamine 
in vivo, while at the same time being completely odourless and tasteless.  If 
the compounds could be designed to allow once daily dosing (instead of the 
current 6h dosing of cysteamine) this would also be advantageous.  A 
number of pro-drugs have been successfully produced and evaluated by a 
team of researchers at the Robert Gordon University.138,139,140,141,143   
 
The first class (or first generation) pro-drugs synthesised in this programme 
were a number of long chain fatty acid amide derivatives of cysteamine and 
cystamine.138 These compounds were deliberately designed to be poorly 
water soluble.  This strategy was adopted in an attempt to neutralise the 
unpleasant taste of cysteamine.  For a substance to be tasted, it must first 
dissolve in saliva in the mouth.  Compounds with low aqueous solubility are 
unable to dissolve in the mouth and so are not tasted.138 This approach has 
been widely used to mask the unpleasant taste of antibiotics, such as 
chloramphenicol182 and other therapeutic agents. A second generation of 
polyethylene glycol (PEG) derivatives of cystamine (pegylated pro-drugs) 
were then produced.  These compounds extended the pro-drug concept by 
the use of a more water-soluble aliphatic linker as a spacer moiety.  PEG is 
a non-toxic, non-immunogenic, non-antigenic polymer which is highly 
soluble in water.  Importantly, modification of a compound by attachment 
to PEG greatly extends the half life of the compound 183. It was envisaged 
that this extension to half life may allow the possibility of less frequent oral 
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dosing in the treatment of cystinosis. PEG also had the advantage of a long 
track history of safety in pharmaceutical use.139   
These novel pro-drugs were non toxic and were shown to deplete 
intracellular cystine levels, in some cases even with greater ability than the 
parent drug, cysteamine.138,139  The problem with the first and second 
generation pro-drugs, however, was a lack of potency. The compounds 
were as active (or slightly more active) than cysteamine itself, and were 
therefore not sufficiently potent to be considered for further development as 
therapies for cystinosis.138,139   
 
In an attempt to increase the potency of the compounds, and to utilise 
completely the existing library of non-toxic building blocks, a third 
generation of ‘multi dose’ pro-drugs was designed and synthesised in 
house.140 These compounds used succinic and glutaric acids as simple, 
biologically acceptable linkers and were designed to incorporate multiple 
cysteamine molecules in their structure.  It was anticipated that alternate 
organic acid – cystamine amides could be built up sequentially to yield a 
long chain molecule which would release multiple copies of cysteamine if 
hydrolysed completely. These derivatives were produced in good yield and 
displayed little or no cytotoxicity when tested in vitro.140  When the efficacy 
of the compounds was determined, they were found to be slightly more 
potent than cysteamine, but did not provide the desired increase in effect.  
Even though they had been designed to yield up to 4 molecules of 
cysteamine when hydrolysed, they proved to be only 1.5 times more 
potent.  This drop in activity was attributed to incomplete hydrolysis of the 
parent pro-drug within the time scale of the assay.140 
 
As part of the project to improve the delivery of cysteamine to cystinotic 
cells, a folic acid derivative of cysteamine was synthesised and evaluated.  
This compound was designed to utilise the existing folate uptake 
mechanism which remains functional in cystinosis.141   The folate pro-drug 
was evaluated in cultured cystinotic fibroblasts and displayed the greatest 
ability to reduce intralysosomal cystine seen so far in our studies.141  
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Chemical structures of each of the pro-drugs mentioned above can be found 
in Chapter 1, section 1.5. 
The work described herein continues the programme of pro-drug synthesis 
and the production of novel ‘multi dose’ pro-drugs designed to release 
multiple cysteamine molecules when hydrolysed (see Figure 52).  The 
overall aim of all of the work remains the design of an odourless and 
tasteless oral therapy for the treatment of cystinosis. 
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                             Figure 52.:  Peptide synthesis of  “ multi-dose” pro-drugs 
 
 
 
 
Cystamine 
Add Fmoc-
succinic/glutaric 
acids 
Attach solid 
support 
Removal of 
Fmoc 
Fmoc-cystamine-
succinic/glutaric-
resin 
One coupling 
cycle 
Cleavage 
One complete 
cycle 
Repeat 
Two coupling 
cycles Three coupling 
cycles 
Four coupling 
cycles 
Hydrolysis 
“n” Molecules of Cysteamine 
n = 4, 6, 8 
  
 
 
129 
 
4.2.1.   Instrumental Techniques for Identification and 
Characterisation of Derivatives 
 
Mass Spectrometry (MS) and Nuclear Magnetic Resonance (NMR) were the 
instrumental techniques employed to identify and characterise the 
compounds at each stage of the synthesis.   
 
Electron Ionisation Mass Spectrometry (EI-MS) was also employed since it is 
an important technique for the elucidation of unknown structures and, if a 
molecular ion radical is identified, MS provides a rapid method to determine 
the relative molecular mass of the product and hence the number of 
coupling reactions achieved.  Low resolution MS was undertaken to 
determine fully the structure of the synthesised compounds, whereas high 
resolution MS was used to obtain an accurate mass.    
Additionally, 1H NMR was used to obtain a complete structure elucidation of 
the final products and their intermediates.  The resonance of expected 
protons was not found in several spectra.  This was due to the repeating 
nature of the molecular units used to build up the novel pro-drugs as shown 
in Figure 53.  The signals due to individual protons tended to become 
superimposed, and this led to complex and over-lapping spectra which 
reduced the usefulness of the technique for the analysis of structures. 
 
Thin Layer chromatography (TLC), was also used to allow a rapid 
determination of reaction progress as well as providing a simple estimation 
of the purity of compounds produced.184 
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         Figure 53.:  Structure of repeating units of cystamine –succinic pro-drug 
 
 
 
4.2.2. General synthesis Cystamine pro-drug derivatives 3, 7, 11, 14. 
 
The strategy to synthesise all pro-drugs was adopted from the synthetic 
method employed by Omran et al. (2011).  Scheme 1 shows the synthetic 
route to the pro-drugs.140,185 
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                      Scheme 1.:  Synthesis of cystamine pro-drugs 
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The synthesis of the pro-drugs was carried out using peptide coupling 
techniques with tert-butyloxycarbonyl (tBoc) as the protecting group for one 
of the free cystamine nitrogen atoms. This meant that mono Boc-cystamine 
became a key synthetic intermediate for all subsequent synthesis.  During 
the synthesis, carbonyldiimidazole (CDI) was used as an activating agent 
for the coupling reaction.   
CDI incorporates an electron deficient carbon atom making it useful in 
nucleophilic substitution reactions where the carbon can be readily attacked 
as shown in scheme 2.186 
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Scheme 2.:  Nucleophilic substitution at the carbonyl group of succinic anhydride 
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The resulting imidazolide acts as a good leaving group in the synthesis of 
the pro-drug. This occurs because the carboxylic anhydride reacts with CDI 
to produce a corresponding imidazole derivative and carbon dioxide (CO2) 
as illustrated in Scheme 3.  The CO2 produced is lost from the reaction and 
this drives the equilibrium to the right hand side.   
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         Scheme 3.:  Mechanism for synthesis of imidazolide derivative 
 
 
 
 
  
 
 
135 
 
Incorporation of CDI as a leaving group necessitates an additional step over the 
published Omran synthesis, but overcomes the slow rate of reaction between 
carboxylic acids and amines as outlined in scheme 4 below.  
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Scheme 4.:  Reaction mechanism of Carbonyldiimidazole (CDI)  
 
 
4.2.2.1.   Synthesis of Pro-drug (1). [2-(2-{4-[2-(2-{4-[2-(2-tert-
Butoxycarbonylaminoethyldisulfanyl)ethylcarbamoyl]propionylamino}ethyldi
sulfanyl)ethylcarbamoyl]propionyllamino}ethyldisulfanyl)ethyl]carbamic 
acid tert-butyl ester 
         The terminal carboxylic acid groups of (2) were activated in the presence of 
carbonyldiimidazole (CDI) in anhydrous DMF.140,141  However, compared to 
previous studies, the imidazolide derivative (3) was not isolated and was 
coupled with 2 equivalents of mono-Boc-cystamine in anhydrous DMF in situ 
to yield the corresponding cystamine derivative (1).  By omitting the 
isolation of the intermediate (3), the percentage yield (83%) of the reaction 
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was improved when compared to previous studies where the percentage 
yield was only (60%).  
         Compound (1) was then characterised by mass spectrometry which gave a 
signal at m/z 821 [M+ 1] corresponding to a relative molecular mass of 
820.  The structure of the N-protected compound was confirmed by proton 
NMR spectroscopy that showed the presence of the tBoc-protecting group as 
an 18-proton singlet centred at 1.37 ppm and the amide NH as a four-
proton triplet at 8.08ppm.   All remaining protons were fully assigned.  
Deprotection of compound 1 with TFA gave the trifloroacetate salt (4), the 
structure of which was confirmed by proton NMR spectrum and mass 
spectrometry which gave a signal at m/z 621[M + 1] corresponding to 
RNH3
+ and a relative molecular mass of 620. 
 
         4.2.2.2.   Synthesis of Pro-drug (5). [2-(2-{4-[2-(2-{4-[2-(2-tert-
Butoxycarbonylaminoethyldisulfanyl)ethylcarbamoyl]butyrylamino}ethyldisu
lfanyl)ethylcarbamoyl]butyrylamino}ethyldisulfanyl)ethyl]carbamic acid 
tert-butyl ester 
 
The product yield for this reaction was also improved when compared to 
previous studies.140  The compound was characterised by mass 
spectrometry which gave a signal at m/z 849 [M+ 1] corresponding to a 
relative molecular mass of 848.  The structure was confirmed by proton 
NMR spectroscopy that showed for example an additional ethyl group in the 
glutaric acid molecule which was identified as a 4 proton multiplet at 1.77 
ppm.  All remaining protons were fully assigned.   
 
Deprotection of compound 5 with TFA was confirmed by the absence of the 
tBoc-protecting group on the 1H NMR spectrum.  All remaining protons of 
the trifloroacetate salt structure (8) were fully assigned and the MS showed 
a signal at m/z 649 [M + 1] corresponding to RNH3
+ and a relative 
molecular mass of 648. 
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4.2.2.3.   Synthesis of Pro-drug (9).  di-tert-butyl ((9Z,21Z)-10,21-
dimethyl-8,11,20,23-tetraoxo-3,4,15,16,27,28-hexathia-7,12,19,24-
tetraazatriaconta-9,21-diene-1,30-diyl)dicarbamate. 
 
The synthesis of pro-drug 9 was complicated by the fact that the presence 
of a double bond in citraconic acid gives the possibility that a side reaction, 
could occur due to a Michael addition mechanism.  The addition of CDI to 
the dicitraconic cystamine had the potential to form a highly activated 
Michael acceptor as shown in Scheme 5. 
 
  
 
 
138 
 
 
          
       Scheme 5.:  Mechanism of Michael addition 
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Despite the theoretical possibility for Michael addition, the desired diamide 
(C) was synthesised and characterised by mass spectrometry (EI/CI) which 
gave a signal at m/z 375 [M – H+] corresponding to a relative molecular 
mass of 376.  
Another indication of the effect of the double bond in the synthesis was the 
formation of a red reaction product.  This product strongly suggested the 
presence of a chromophore and may be due to through conjugation 
between the citraconic double bonds and the carbonyl imidazole. 
Furthermore, the synthesis using this type of acid produced diamides C and 
D with a low yield when compared to diamides A and B as outlined in Table 
17.   
 
Table 17.:  Effects of Michael addition on the yield of diamides C and D 
 
Diamide Mass of final product (G) % Yield of final product 
 (A) 0.46 92 
 (B) 0.36 72 
 (C) 0.16 27 
 (D) 0.27 59 
 
 
This suggests that the side reaction due to a Michael addition, even though 
the Michael product could not be isolated, may be having a detrimental 
effect on the final yield as shown in Table 18 below. 
The final product (11) was characterised by mass spectrometry which 
yielded a signal at m/z 879 [M + Cl-] corresponding to a relative molecular 
mass of 844. Mass spectrometry also showed the presence of the starting 
material Monoboc cystamine which had a signal at m/z 253 [M + H+] 
suggesting the low yield may also be due to incomplete reaction. 
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4.2.2.4.   Synthesis of Pro-drug (12).  di-tert-butyl ((9Z,21Z)-
8,11,20,23-tetraoxo-3,4,15,16,27,28-hexathia-7,12,19,24-
tetraazatriaconta-9,21-diene-1,30-diyl)dicarbamate. 
 
The synthesis of this compound was also affected by the presence of a C=C 
in the starting acid. Nevertheless, the synthesis produced the desired 
diamide (D) which was characterised by mass spectrometry (EI/CI) which 
had a signal at m/z 347 [M – H+] corresponding to a relative molecular 
mass of 348.   
However, the yield of the final product (12) was also low (see Table 18) and 
this is attributed to the Michael addition discussed above.   
 
Table 18.:  Effects of Michael addition on the yield of final products 
 
Compound Mass of final product 
(G) 
% Yield of final product 
(1) 1.94 83 
(5) 1.64 73 
(9) 0.19 38 
(12) 0.37 41 
 
 
The final product (12) which was also coloured red and was characterised 
by mass spectrometry to give a signal at m/z 419.5 corresponding to a 
relative molecular mass of [816 + Na]/2.  Starting material could not be 
identified in the mass spectrum, suggesting that this reaction did proceed to 
completion.  
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4.3.   Synthesis of Cystamine Pseudo-Peptides. 
 
In an attempt to increase the overall efficacy of the compounds, target 
molecules which could release multiple cysteamine residues were designed.  
These compounds, if hydrolysed completely in vivo, would release multiple 
molecules of cysteamine and it was envisaged this would increase the 
potency of the drug. 
A small library of pro-drugs was synthesised using Fmoc-based solid phase 
peptide synthesis techniques which is now the method of choice for the 
routine synthesis of peptides.  The hindered base-labile N-Fmoc group was 
used to protect the -amino function of amines which is also compatible 
with tert-butyl-based side-chain protection. 
The required protected amino acids were not commercially available and 
amino acids 15 and 16 were prepared as described in Chapter 3, section 
3.2.1.  
 
       4.3.1.   General Synthesis  
 
All novel cystamine pseudo-peptides were synthesised using a cycle of 
reactions incorporating TBTU/HOBt activation as shown in Figure 54.   
 
TBTU was used to convert the Fmoc amino acid into the active OBt ester in 
the presence of DIPEA.  The aromatic ester HOBt becomes the activated 
ester which can be easily hydrolysed and can also react with a wide range 
of nucleophiles.187 Under mild conditions HOBt reacts minimally with amines 
usually with reduced racemisation of the alpha carbon atom.  In peptide 
synthesis, HOBt is one of the most commonly used coupling reagents 
because of the electron-withdrawing nature of its particular alcohol resulting 
in the increased electrophilicity of the carbonyl centre.187  
Furthermore, the presence of hydroxyl group (OH) in the carboxylic acid of 
amino acids 15 and 16, acted as good leaving groups in the formation of an 
amide bond between the two amino acid residues. 
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Figure 54.:  Solid phase peptide synthesis (SPPS) steps with Fmoc-chemistry.  
Reagents and conditions: [1] HOBt, TBTU, DIPEA, DMF, RT, 2 h; [2] 20% 
piperidine, RT, 2 h; [3] DMF; [4]  HOBt, TBTU, DIPEA, RT, 2 h; [5] DMF; [6] 1% 
TFA, RT, 2 h. 
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4.3.1.1.   Synthesis using Solid Phase Peptide Synthesis (SPPS) and 
Convergent Peptide Synthesis (CPS). 
 
In a typical peptide coupling reaction, the carboxylic acid moiety of the 
amino acid 1 is first activated by an appropriate peptide coupling reagent, 
and then reacted with the amine moiety of the amino acid 2 to produce a 
desired peptide as illustrated in Scheme 6.188  
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                             Scheme 6.:  General synthesis of peptides 
 
 
All peptides were synthesised in a relatively facile manner on three different 
solid supports (resins) using a standard protocol for TBTU/HOBt/DIPEA 
activation of Fmoc protected cystamine derivatives. 
The synthesis followed the stepwise assembly of peptides by consecutive 
coupling of compound 15 or 16 which were the common starting materials 
in the synthesis of the peptides. 
The first step in synthesis was to incorporate compound 15 or 16 onto the 
solid support through an ester linkage and the reaction was monitored by 
TLC.  The N protected group was deprotected under conditions which did 
not cleave the resin-amino acid ester bond (see Scheme 7).  Another Fmoc 
protected cystamine derivative 15 or 16 was coupled to the amino group of 
the resin bound substrate via an amide coupling. The resulting peptide bond 
was formed due to the condensation reaction usually initiated by activation 
of the carboxylic acid component as shown in Scheme 7.189 
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                       Scheme 7.:  Peptide bond formation  
 
The N deprotection and coupling steps were repeated until the desired 
sequence was assembled on the resin.  The final step in the process was to 
cleave the resulting sequence from the support with 10% TFA giving rise to 
the free pseudo peptide which was characterised by mass spectrometry (see 
Table 19 below). 
 
Table 19.:  Mass spectrometry (MS) results  
 
Peptide HR-MS  LR-MS 
17 (M + H+) 765.2583 (100%)  
18 (M + H+) 999.3070 (55%) 
19 (M + H+) 545.2255 (100%)  
20 (M + H+) 793.2900 (100%) 
21  No recognisable peak 
obtained 
22 (M + H+) 1289 (25%) 
 
23 (M + H+) 779.2738 (80%)  
24 (M + H+) 780.2226 (100%) 
25 (M + H+) 808.2537 (100%) 
Weak 
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26 (M + H+) 794.2379 (65%) 
27 (M +H+) 937.3330 (15%) 
28 (M + H+) 965.3636 (100%)  
29 (M – H+) 949.3283 (100%) 
30  (Mass + H+)   987 (20%)  
(M + K+) 1025 (55%) 
 
31 (M + Cl-) 1049 (100%) 
(M + H+) 1015 (15%) 
(M + Na+)  
1037 (35%) 
32 No identifiable peaks were 
obtained 
33 No identifiable peaks were 
obtained 
34 Mass 1292 (10%) 
35 No identifiable peaks were 
obtained 
36  (M + H+) 531 (100%) 
 
 
H-Lys(Boc)-2-Cl-trt resin (Lys) and H-Ala-2-Cl-trt resin (Ala) consistently 
generated peptides with a similar yield when compared to peptides 
synthesised using  1, 3-Diaminopropane trityl resin (DAP) as shown in 
Table 20.  
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Table 20.:  Peptides generated from solid phase peptide synthesis (SPPS) 
using different solid support resins and convergent peptide synthesis (CPS). 
 
Resin Peptide Mass of final 
product (G) 
% Yield of final 
product 
DAP 
 
Fmoc(2CS)-DAP (17) 
Fmoc(3CS)-DAP (18) 
Fmoc(CG)-DAP (19) 
Fmoc(2CG)-DAP (20) 
Fmoc(4CG)-DAP (22) 
Fmoc(CS-CG)-DAP (23) 
Fmoc(CS)-DAP (36) 
 
0.1 
0.55  
0.1  
0.4  
0.25  
0.076 
0.05 
 
10 
11 
29 
15 
5 
8 
15 
 
Ala 
Fmoc-2CS-Ala (24) 
Fmoc-2CG-Ala (25) 
Fmoc-CS-CG-Fmoc-Ala 
(26) 
0.09 
0.07  
0.08 
 
13 
10 
11 
Lys Fmoc-2CS-BocLys (27) 
Fmoc-2CG-BocLys (28) 
Fmoc-CS-CG-BocLys (29) 
0.15 
0.2 
0.18  
13 
11 
10 
CPS Fmoc-CS-DAP-SC-Fmoc 
(30) 
Fmoc-CG-DAP-GC-Fmoc 
(31) 
Fmoc-2CS-Lys(Boc)-Fmoc-
cystamine (34)    
0.2 
 
0.13  
 
0.09 
 
18  
 
23 
 
10 
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Attempts were made to improve the yields obtained using the DAP resin by 
increasing the stoichiometric amounts of resin, and also the reaction 
temperature, however, the yield remained low.  Solid phase peptide 
synthesis is often selected for the production of small peptides.  The resulting 
peptides would often have a yield not exceeding 100 mg.189 
In addition, the longer the sequence, the greater the number of coupling 
cycles required and the lower the yield produced.  This was seen with 
peptides 18 and 22 (Table 20). 
 
Other problems which could have contributed to the low yields obtained 
during peptide synthesis were the formation of side reactions residues such 
as urea.  Previous studies showed that during peptide synthesis using for 
example DCC as the coupling reagent, the highly reactive 0-acylisourea is 
formed which in turn reacts with the amine to produce the peptide and urea 
derivative.190 
 
Incomplete coupling could have also been a contributing factor in obtaining 
peptides with low yields.  This was confirmed by the production of a reddish-
brown colour produced by the ninhydrin reaction as described in chapter 3, 
section 4.2.4.1.4, indicating a positive reaction to an incomplete coupling.  
 
In addition, the presence of sulfur in the starting reagents could allow REDOX 
type reactions to reduce further the yields obtained.  Previous studies by 
Antonkine et al. reported the formation of iron-sulfur clusters with relatively 
low yield of 17% during a standard Fmoc-synthesis.  The presence of a large 
amount of cysteine residues may have contributed to the low yield obtained, 
giving that cysteine commonly undergoes a number of side reactions during 
peptide synthesis.191  
In order to increase the library of compounds produced for biological 
evaluation, it was decided to adopt a convergent peptide synthesis.  
Compounds 19 and 36, produced from sequential linear peptide synthesis 
were used to produce new peptides via a convergent approach.  
The overall yield of these peptides was higher than that obtained from linear 
synthesis as seen in Table 20.  
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Moreover, using the convergent approach allowed us to carry out the 
chemistry with relatively small fragments.   
 
4.3.1.2.   Attempted synthesis using Convergent Peptide Synthesis 
(CPS) 
 
The convergent approach was repeated with compounds 32, 33, and 35, 
(refer to the structure library).   
Although a product was isolated, no identifiable peaks were obtained 
following characterisation by mass spectrometry as shown in Table 19.   
However, MS results for compound 33 and 35 showed the presence of both 
starting materials; refer to Chapter 3 section 3.2.7.4 and 3.2.7.5 respectively 
for details. 
These results could have also been due to multiple ionisations of the product 
or instability in the desired product.  
 
Throughout the synthesis of the peptides, routine TLC was used to monitor 
the reactions.  The use of preparative HPLC was investigated as a more 
efficient method to purify the synthetic products.  Suitable chromatographic 
conditions were identified using a 4.6mm, C18, reverse phase analytical 
column, but resolution and peak separation were reduced when the 
separation was scaled up to prep or semi-prep quantities.  This was not 
unexpected and was attributed to a loss of resolution with the larger prep 
column.  Further optimisation of the technique was becoming time 
consuming, and as a result, this method of separation was not pursued. 
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4.4.   Biological studies 
 
A small number of synthesised compounds were evaluated for cell toxicity 
and their ability to reduce the levels of cystine in cultured cystinotic cells. 
Statistical analysis of both the cytotoxicity and activity data was carried out 
using Paired t-tests and One-way ANOVA analysis.  
 
4.4.1. Cytotoxicity  
 
A small number of synthesised cystamine pseudo peptides were selected and 
evaluated for their growth inhibitory and cell toxicity effects on cystinotic 
fibroblasts.  The criterion for selection comprised of the sample size and the 
representation of each class of compounds.  This study was developed and 
conducted in our laboratory using the Alamar Blue cell proliferation assay as 
described in Chapter 3 section 3.3.3.2.  
This assay was based on the use of an indicator dye developed to measure 
and quantify cell growth in cultured cells.  The mechanism by which the 
Alamar Blue dye works is by an oxidation-reduction (REDOX) reaction.  Live 
cells are able to metabolically convert the blue dye (resazurin) to a pink 
coloured compound (resofurin). The intensity of the resulting colour was 
quantified using a spectrophotometer at a wavelength of 570nm which is the 
 max for the reduced compound.  The values obtained were proportional to 
the growth of the cells in the cell culture plates and are represented 
graphically in Figure 55. 
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Figure 55.:  Graph showing cell growth in presence of cysteamine and compounds 
1-6 (50µM) over a 72 hour incubation. Cytotoxicity was determined by Alamar Blue 
Assay.  Data are mean ± SD of 3 independents experiments (n = 3).  Each 
measurememt was carried out in triplicate. 
     
       Compound 1   Fmoc-3x (CystSucc)-DAP 
 Compound 2   Fmoc-(CystGlut)-DAP 
 Compound 3   Fmoc-(CystSucc-CystGlut)-Lysboc 
 Compound 4   Fmoc-2x (CystGlut)-Ala 
 Compound 5   Fmoc-2x (CystGlut)-Lysboc 
 Compound 6   Fmoc-2x (CystSucc)-Lysboc 
 
The results in Figure 55 clearly show that all of the synthesised pro-drugs 
(1-6) gave a growth profile similar to the vehicle (0.5% DMSO) and all were 
less toxic than cysteamine itself. As expected, the most significant period of 
cell growth was evident in the first 20 hours for all of the samples tested.  
The net increase of all samples tested was lower at 20 hours when compared 
to the untreated cell control. By approximately 48 hours, no drop in growth 
was observed as the cells would have probably reached confluence, rather 
than any inherent toxic effect. These results are not unexpected, since 
previous work in our laboratories, using similar compounds (7, 8, and 9), 
has not resulted in substantial levels of cytotoxicity as seen in Figure 56.  
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The pro-drugs synthesised are composed of repeating units of endogenous 
compounds (succinic acid, glutaric acid, cystamine, etc.) which are known to 
be non-toxic to cells. 
 
 
 
 
 
Figure 56.:  Graph showing cell growth of  cysteamine and compounds 7-9 (50µM) 
over a 48 hour incubation. Cytotoxicity was determined by Alamar Blue Assay.  Data 
are mean ± SD of 3 independents experiments (n = 3).  Each measurememt was 
carried out in triplicate. 
 
Compound  7  Fmoc-x2 (CystSucc)-DAP 
Compound  8  Fmoc-x2 (CystGlut)-DAP 
Compound  9  Fmoc-(CystSucc-CystGlut)-DAP 
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4.4.2. Effect of synthetic pro-drugs on levels of cystine 
 
A commercially available Thiol assay kit (Fisher Scientific, UK) was used 
along with the Bradford Protein assay to evaluate the efficacy of the novel 
compounds in reducing the cystine levels in cultured cystinotic fibroblasts.  
The assays are described in Chapter 3, sections 3.3.4.1 and 3.3.4.2 
respectively. 
The results of these assays are presented in Figure 57.  However, due to 
the small sample number (results are the average of 3 observations) these 
data should be regarded as preliminary. The results were analysed using 
independent sample unpaired t-tests which showed some differences 
between the samples.   
Compounds 3, 4, 5, 7, 10, and 11 resulted in a significant decrease in 
cystine level when compared to the Vehicle Control.  (Figure 56) 
Compound 6 although non toxic, generated an abnormally high set of 
results when compared to previous studies.  
Ideally, these measurements should be repeated using replicates of up to 
9 observations to provide results which are statistically rigorous, however, 
there was insufficient sample available for some of the synthesised pro-
drugs which curtailed the replicates for the experiment. 
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Figure 57.:  Relative cystine depletion in cystinotic fibroblasts measured following  
a 24 hour incubation with cysteamine and compounds 3-11 (50µM).  Data are 
mean ± SD of 3 observations.  Each measurememt was carried out in triplicate. 
The level of significance was determined using independent sample unpaired t-
tests. 
 
 
 Compound 3   Fmoc-(CystSucc-CystGlut)-Lysboc     
 Compound 4   Fmoc-2x (CystGlut)-Ala 
 Compound 5   Fmoc-2x (CystGlut)-Lysboc 
         Compound 6 Fmoc-2x (CystSucc)-Lysboc 
         Compound 7   Fmoc-2x (CystSucc)-DAP 
         Compound 10 Fmoc-3x (CystSucc)-DAP 
         Compound 11 Fmoc-(CystGlut)-DAP    
 
The result for Compound 6 appeared completely anomalous and the cystine 
values (1.115 per mg of protein) obtained far exceed any values seen 
during previous work on cysteamine pro-drugs.  This anomalous result is 
potentially attributed to poor aqueous solubility.  Compound 6 displayed 
only limited aqueous solubility and it proved difficult to get the drug into 
solution.  It is proposed that, once added to the cell suspension, Compound 
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6 may have precipitated from solution and this would have contributed to 
an anomalously high absorbance reading. This is particularly true if particles 
of drug were present in the sample, which could scatter light during the 
spectrophotometric assay.   
 
Compounds 3, 5, and 7 and in particular 4, 10, and 11 displayed a 
significant reduction of lysosomal cystine levels when compared to the 
vehicle control and cysteamine.  This is an encouraging result and suggests 
that the synthesised pro-drugs are active in reducing the cystine levels in 
these cells.  We propose that this effect is due to intracellular hydrolysis of 
the pro-drugs to yield free cysteamine which is able to cleave the disulfide 
bond in cystine as described in the Introduction. It is possible that the pro-
drugs are decomposing in the extracellular medium and released 
cysteamine is entering the cells to reduce the cystine burden, however, the 
delay in onset of action suggests that the pro-drugs are being absorbed 
intact and then breaking down within the cell to release the active agent. A 
definitive answer would require analysis of the intracellular contents to 
determine the presence of intact prodrug but this was not possible during 
this study. 
 
Furthermore, the drug design rationale for these compounds required 
complete hydrolysis of the amide linkages in the pro-drug to release 
multiple molecules of cysteamine (6 to 8 cysteamine molecules depending 
on the pro-drug).  These results do not show that the pro-drugs were 6 to 8 
times more effective than cysteamine, which strongly suggests that 
hydrolysis was incomplete in the time course studies here.  It is also 
possible that some of the amide bonds in the pro-drugs are more highly 
resistant to hydrolysis, by intracellular amidases and in solution, than 
others.  
 
The result for cysteamine is also anomalous.  This compound is clinically 
proven to reduce the cystine level of cells, but in this assay, the levels for 
cysteamine are not significantly different to the control.  A possible reason 
for this is oxidation of cysteamine to cystamine in the course of the 
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experiment. The thiol group of cysteamine oxidises readily to a disulfide and 
this precludes formation of the mixed disulfide and a reduction in the levels 
of cystine.  These studies would have to be repeated in the absence of 
oxygen (e.g. under an inert atmosphere in a glove box using degassed 
solutions) to allow a conclusion to be reached.  Cysteamine and cystamine 
exist in a REDOX equilibrium192 and the proportion of the oxidised or 
reduced species depends on the environment in the cells.   
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CHAPTER 5 
 
CONCLUSIONS 
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5.1.   Conclusion and future work 
Throughout the whole of the crystallography work described in this project, 
the objective has been to synthesise and evaluate novel co-crystals of 
cysteamine and cystamine, as part of our desire to produce odourless and 
tasteless oral therapies for cystinosis.  Despite our best efforts we have 
failed to produce novel cysteamine/cystamine co-crystals, but the work has 
generated a series of novel cysteamine and cystamine salts which were fully 
characterised by melting point (mp), Differential Scanning Calorimetry 
(DSC), infra-red (IR) spectroscopy and Xray diffraction.  However, further 
work is required to determine the cytotoxicity of these novel salts and 
assess their ability to deplete the high cystine levels associated with 
cystinosis. Moreover, in an attempt to resolve the problems associated with 
the formation of salts with cystamine, more work is required to try to 
synthesise co-crystals rather than salts.  Salts are formed when ionisation 
occurs and a proton is transferred from acid to base. The possibility of 
proton transfer should be reduced by using weaker acids with a higher pKa 
and through inactivation of the amine functional group of cystamine by, for 
example, substitution with an electron withdrawing substituent (e.g. a 
phenyl ring).  This reduction in basicity should favour co-crystal formation 
(where no proton transfer occurs) over salt formation where a proton is 
exchanged.  
Another way of improving the analysis of co-crystals would be to analyse 
the product using neutron diffraction techniques, instead of beams of X-
rays, allowing a more accurate location of the hydrogen atoms.  However, 
to fully utilise this technique, a robust scientific rationale will be required 
and an approximate location for the hydrogen atoms should already be 
established.  Additionally, establishing a comprehensive screening process 
using different co-formers may be the way ahead for co-crystal production. 
This research project has also shown that a series of multicysteamine pro-
drugs (i.e. pro-drugs which may hydrolyse in vivo to release up to six 
molecules of cysteamine per molecule of pro-drug) can be successfully 
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synthesised in good yields.  Although the main synthetic route employed 
was not novel and followed a method pioneered by Omran et al. (2011), we 
have demonstrated that by adopting an in-situ approach in one of the 
reaction steps, the yield of the final product has been improved and the 
overall reaction simplified.  The synthesised pro-drugs were fully 
characterised by NMR spectroscopy and mass spectrometry before biological 
evaluation using techniques of cell culture. 
In addition, work has also been undertaken using other carboxylic acids 
such as maleic acid and citraconic acid as starting materials.  However, 
synthesis using these particular acids produced compounds in low yields.  It 
has been suggested that an alternative reaction mechanism via an 
undesired Michael addition could have been a factor in limiting the yield 
obtained. A definitive answer could be obtained by repeating the synthesis 
with other unsaturated carboxylic acids, isolating and fully characterising 
the Michael product. 
In order to build up our library of compounds further, solid phase peptide 
synthesis was employed using three different resin supports.  Although this 
type of approach produced good results, the yield of the final peptides was 
very low.   Therefore, in order to improve the yield and purity of the 
synthesised compounds, the next logical step would be to try other solid 
support resins and vary the reaction conditions (e.g. replacement of TBTU 
by dicyclohexylcarbodiimide [DCC] or diisopropylcarbodiimide [DIC] as 
dehydrating agent with HOBT or hydroxysuccinimide to minimise unwanted 
side-reactions, could be pursued).  Further work in this area should also 
involve the optimisation of a robust preparative or semi-prep HPLC method 
for the purification of synthetic products.  
Finally, all the work described herein has concentrated on the design of pro-
drugs able to form a mixed disulfide with cystine, which is isosteric with the 
amino acid lysine.  It should be noted that there are a number of other 
amino acid transporters present in lysosomal membranes.193   It may be 
that pro-drugs designed to target these transporters would provide a future 
source of agents active in the treatment of cystinosis. 
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Appendix 2 
 
 
 
 
 
 
 
                       Figure A.1.:  1H spectra of Cystamine Succinate [1]  
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              Figure A.2.:  1H spectra of N,N’-Disuccinoylcystamine [2] 
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                        Figure A.3.:  1H spectra of Cystamine Glutarate [5] 
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                    Figure A.4.:  1H spectra of N,N’-Diglutaroylcystamine [6] 
 
 
 
 
 
 
 
Figure A5.:  1H spectra of Fmoc-cystamine-succinate [15] 
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                 Figure A9.:  1H spectra of Fmoc-cystamine-glutarate [16] 
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Appendix 3 
 
 
 
                            
        Figure B.1.:  MS for N,N’-Citraconoylcystamine [10] 
 
 
 
 
        Figure B.2.:  MS for N,N’-Maleioylcystamine [13] 
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         Figure B.3.:  MS for Fmoc2CSDAP [17] 
 
 
 
 
            
         Figure B.4.:  MS for Fmoc3CSDAP [18] 
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                              Figure B.5.:  MS for FmocCGDAP [19] 
 
 
 
 
 
                           
                              Figure B.6.:  MS for Fmoc2CGDAP [20] 
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                            Figure B.7.:  MS for FmocCSGDAP [23] 
 
 
 
 
 
 
                          
                             Figure B.8.:  MS for Fmoc2CSAla [24] 
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                       Figure B.9.:  MS for Fmoc2CGAla [25] 
 
 
 
 
 
                           
                              Figure B10.:  MS for FmocCSCGAla [26] 
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                               Figure B.11.:  MS for Fmoc2CSBocLys [27] 
 
 
 
 
 
                         
                             Figure B.12.:  MS for Fmoc-2CG-BocLys [28] 
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                              Figure B.13.:  MS for FmocCSCGBocLys [29] 
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